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Abstract 
Mycobacterium tuberculosis (MTB) is an obligate intracellular human pathogen that causes 
tuberculosis (TB) disease. Today, TB is the leading cause of death from a single infectious agent and 
ninth leading cause of death globally. Increasing burden of drug-resistant TB is threatening the 
achievements and targets set by World Health Organisation (WHO). With the recent advances in 
whole genome sequencing (WGS) technology, there is renewed hope for its role as a ‘game changer’ 
towards eliminating TB. This thesis focusses on the utility of WGS technology on MTB strains 
circulating in Far North Queensland (Australia) and Western Province (Papua New Guinea) for 
extensive understanding of molecular epidemiology and evolutionary dynamics that are important for 
improved TB management. Western Province, Papua New Guinea (PNG) which neighbours Far 
North Queensland has one of the highest numbers of drug resistant TB globally. Various efforts are 
being made to control the epidemic spread of TB within this region and the surrounding areas. 
  
In the first research study (chapter 2), isolates from Daru (capital town, Western Province) were first 
analysed using a conventional genotyping method (MIRU-VNTR) which identified high level of 
strain relatedness indicative of ongoing transmission. On application of WGS, four different clades 
of a dominant modern Beijing strain were identified. Molecular markers that contribute to 
development of drug resistance, virulence and transmission were characterized. Molecular dating of 
the dominant strain suggested a long evolutionary history, estimated to have started in the 1940s and 
early acquisition of streptomycin and isoniazid resistance markers in the 1950s. Some of the identified 
genomic markers within the Beijing strain highlight possession of plausible biological mechanisms 
that contribute to the on-going transmission of drug resistance in the study setting and threaten further 
spread to other regional areas. 
 
In the second study (chapter 3), both genomic and epidemiological data were exploited to understand 
the diversity of strains circulating among PNG nationals (cross-border patients) who sought TB 
services at Australian clinics within the Torres Strait. This is part of understanding the prevailing 
transmission dynamics within the Torres Strait Protected Zone (TSPZ). This zone has free movement 
of people (no visas) between Australia and PNG territories. Modern Beijing strain was identified to 
be the most prevalent strain, and it was significantly associated to transmission especially among 
patients from the same locality. As ‘proof of principle’ for cross-border transmission among nationals 
of either countries in TSPZ, four epidemiologically linked Australians isolates (within the Torres 
Strait) were characterized to have attained the same a drug resistant Beijing strain from PNG. This 
highlighted the need for enhanced co-operation among regional authorities for improved surveillance 
of TB and the necessity for integration of WGS into the regional surveillance program.  
III 
 
 
It should be noted that during genomic analysis of the two above mentioned research studies, variants 
within genomic regions such as proline-glutamate/proline-proline-glutamate (PE/PPE) gene families 
were consistently filtered out as they were considered spurious. These regions have a rich GC content 
and repetitive in nature which makes it difficult to study using short-read sequencing data like 
Illumina. Moreover, the diversity within these genes is thought to contribute to the diverse 
pathogenicity, immunogenicity and virulence among MTB strains. So in the third study (chapter 
four), Oxford nanopore technologies (ONT) which is known to produce long reads and high depth 
sequence data was utilized on an extensively drug resistant (XDR) strain as proof of principle for its 
applicability. This technology did not only provide unparalleled resolution to assemble the first 
circular XDR genome that included the PE/PPE genes, it also unravelled novel variations within these 
regions hence highlighting some of the mechanisms played by these genes towards immunogenicity 
and virulence. Unique structural variants were identified from the assembled genome and it has 
potential to serve as a local reference genome for future MDR/XDR surveillance. 
 
In conclusion, WGS provided greater insights into the molecular basis of resistance, evolution and 
transmission dynamics of strains circulating in Western province, PNG, Torres Strait and North 
Queensland. Future assessment of dominant modern Beijing strains’ extent of spread to wider areas 
of PNG and north Queensland will be required. Analysis performed indicated significant clinical and 
public health benefit towards strengthening TB surveillance programs and improve TB patient 
management. ONT demonstrated its usefulness in providing further insights into the genetics of an 
XDR MTB strain, though further evaluation of its use is needed in high burdened settings.     
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1.0 Chapter 1: Introduction 
1.1 Global tuberculosis burden 
Mycobacterium tuberculosis (MTB) is the leading global cause of infectious disease and ninth leading 
cause of death globally (1). In 2016, 10.4 million estimated incident cases of tuberculosis (TB) were 
noted, of which 87% were from the 30 high TB burden countries (Figure 1.1). The regions with the 
highest numbers of cases include South-East Asia region (45%), African region (25%) and Western 
Pacific region (17%). The number of cases from countries including India, Indonesia, China, 
Philippines and Pakistan account for 56% of the total number of global TB cases.  In 2016, there were 
an estimated 1.3 million and 374,000 deaths among HIV-negative and HIV-positive TB cases 
respectively. The mortality rate varies considerably among countries with ranges of less than one TB 
death per 100,000 population in high resourced countries to 40 or more deaths per 100,000 population 
in low resource countries such as those in the African region, some Asian countries (Bangladesh, 
Indonesia, Myanmar, and the Democratic People’s Republic of Korea) and Asia-Pacific countries 
including Papua New Guinea and Kiribati.  
 
 
Figure 1.1: Estimated tuberculosis incidence rates, 2016. (adopted from WHO Global Tuberculosis 
Report, 2017(1)) 
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1.1.1 Tuberculosis burden in Australia  
With a population of 24 million, Australia has one of the lowest TB incidence rate estimated to be 
6.1 per 100,000 population in 2016 (1) and the low incidence has been maintained for decades. A 
substantial decline in the rate of TB happened in the 1960s was due to a combination of factors such 
as improved living standards, mass education, vaccinations and anti-TB drugs; and the incidence rate 
has steadily been maintained between 5-8 cases per 100,000 population since the mid-1980s (Figure 
1.2). Both New South Wales and Victoria states account for approximately two-thirds of all the TB 
cases observed between 2012 and 2013 (2). Ninety percent of all the cases are attributed to overseas-
born persons from Asia, southern and eastern European countries, Pacific Island nations, north and 
sub-Saharan Africa (3). The highest proportion of cases are found among permanent residents and 
students, and their infections are attributed to reactivation of diseases rather than transmission within 
Australia (2). By international standards, the notification rate among Australian-born indigenous 
persons is low (<5 per 100,000) yet they experience TB at about 6 times more to that of Australian-
born non-indigenous people (4). The National Health and Medical Research Council (NHMRC) has 
previously attributed the relatively low socioeconomic conditions among indigenous persons as the 
main cause of the higher disease burden in these communities (5). Until inequalities between 
indigenous and non-indigenous populations are addressed, TB rates will not the same in these 
populations (6) 
 
Figure 1.2: Notification rates of tuberculosis in Australia since 1960 to 2013. Rates have significantly 
declined since 1960s and plateaued in mid-1980s (adopted from Toms et al, 2015(4)).
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1.1.2 Tuberculosis burden in Queensland 
The Queensland Department of Health is comprised of 16 Hospital and Health Services (HHS) 
responsible for the health of 4.9 million people (7). In 2016, there were 189 notified cases at an 
estimated notification rate of 4.0 per 100,000 (8) with Metro South HHS (n=54) reporting the highest 
number of cases followed by Metro North HHS (n=36). Far north Queensland which constitutes 
mainly Torres-Cape HHS and Cairn-Hinterland HHS have the highest notification rate (7.7 cases per 
100,000, Figure 1.3). The rate of TB among the Aboriginal and Torres Strait Islander is 6.3 times 
(4.4 per 100,000) higher than the rate in Australian-born non-indigenous people (0.7 per 100,000). 
The onset of disease among Australian-born (non-indigenous) is estimated to occur among 60+ years 
old people (range 18-87) compared to 35+ years (range 6 months-90 years) old people born overseas 
(8).  
 
Figure 1.3 A map of Queensland showing the number of cases and notification rate of tuberculosis 
for the different Hospital and Health Service systems in 2016 (adopted from Queensland 
Department Health report, 2017(8)).  
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1.1.3  Tuberculosis burden in Papua New Guinea 
Papua New Guinea is a country neighbouring Australia in the North with an estimated population of 
7.2 million people (9). Globally, it’s the ninth highest TB burned country (1). In 2016, there were 
29,751 notified cases of TB and an estimated incidence rate of 432 per 100,000 population (1). 
According to 2017 TB epidemiological report, 6 provinces; National Central District (NCD), Western 
New Britain (WNB), Gulf, Western, Oro and Morobe constituted 70% (20,000 cases) of the total 
number of TB cases observed in 2016 (10).  
 
Figure 1.4: A map of Papua New Guinea illustrating the different Provinces (adopted from www.d-
maps.com) 
Western Province, PNG shares two international borders; Indonesia’s West Papua (in the west) and 
Australia’s Torres Strait (in the South). As the largest province in PNG, it is divided into three 
districts; north fly, middle fly and south fly. Of the estimated total population of 201,351, 39% occupy 
the middle fly district, 31% occupy the north fly district and 30% occupy the south fly district (9). 
Western Province is naturally rich with mineral resources (gold, copper and iron), petroleum, timber 
and marine resources. It’s the most geographically diverse (swamps, lakes and rivers), arguably the 
most remote and one of the poorest provinces in PNG (11). The provinces’ health system is under 
developed, the characteristic of a low-resource environment with limited financial and human 
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resources to offer the best services. One of the major health care facility offering TB services is 
located at the provincial capital town, Daru (South fly district).  
In 2012, the Western Province was estimated to have a TB notification rate of 500 per 100,000 
population (12), which is almost double the rate defined by WHO for sub-Saharan Africa. On 
recognition of increasing numbers of drug resistant TB, PNG government and its partners (WHO, 
Burnet Institute, Department of Foreign Affairs and Trade of Australia, and World Vision 
International) set up an emergency response team (ERT) in 2014. The ERT assists in raising high-
level advocacy, resource mobilization, planning and monitoring implementation of the national 
response to drug-resistant TB (13). Substantial progress has been made in improving diagnosis, 
treatment and care of TB patients since the establishment of ERT e.g. case detection of drug resistant 
TB increased from 61 cases in 2013 to120 cases in 2015 and 134 in 2016 (13, 14).  
1.2  Aetiological agents of tuberculosis 
Mycobacteria belongs to a class of bacteria known as actinomycetes, order actinomycetales, family 
Mycobacteriaceae and genus Mycobacterium. The family Mycobacteriaceae is gram-positive, non-
motile, catalase-positive and have a rod like-filamentous morphology. According to Frebault and 
Portaels, the genus Mycobacterium are characterized with acid-alcohol fastness,  presence of cell wall 
mycolic acids (60-90 carbon atoms) cleaved to C22 to C26 fatty acid methyl esters, glycolipids, 
polysaccharides and GC content of 61 to 71mol% (15). The microbes’ width and length vary from 
0.3 to 0.6μm and 1 to 5μm, respectively.  
Clinical tuberculosis is caused by an assorted group of Mycobacteria known as Mycobacterium 
tuberculosis complex (MTBC) that comprise of Mycobacterium tuberculosis, Mycobacterium 
africanum, Mycobacterium bovis, Mycobacterium bovis BCG, Mycobacterium microti, 
Mycobacterium canettii, Mycobacterium pinnipedii, Mycobacterium caprae and Mycobacterium 
mungi. MTBC are closely  related at  the  DNA  level  and  share some identical 16S rRNA  gene  
sequences but  have different phenotypes and  host  preference (Table 1.1) (16-18). Human 
tuberculosis is predominantly caused by Mycobacterium tuberculosis and Mycobacterium africanum. 
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MTBC Species Predominant host 
Mycobacterium tuberculosis Humans, domesticated animals 
Mycobacterium africanum Humans, primates 
Mycobacterium bovis Cattle, wild animals 
Mycobacterium bovis BCG Vaccine strain 
Mycobacterium microti Rodents/voles 
Mycobacterium pinnepedii Seals 
Mycobacterium canettii Humans 
Mycobacterium caprae Goats 
Mycobacterium mungi Banded mongooses 
 
Table 1.1: Members of Mycobacterium tuberculosis complex (MTBC) and specific hosts. BCG- 
Bacillus Calmette-Guèrin (17-19) 
1.2.1 Population structure of Mycobacterium tuberculosis complex 
One of the first studies to understand the evolutionary relationship between members of MTBC 
highlighted a genomic region known as TbD1 which spans genes mmpS6 and mmpL6, and categorized 
the population into “modern” (TbD1 deletion) and “ancient” or “ancestral” (without TbD1 deletion) 
(Figure 1.5) (20). Crucially it showed Mycobacterium bovis to be more recently derived than human 
strains which was against a common notion that human tuberculosis evolved from a bovine progenitor 
(21). Two other studies analysed mutations within ‘housekeeping’ genes and categorized 
Mycobacterium tuberculosis population into four lineages (22, 23). The completion of the first 
Mycobacterium tuberculosis reference genome (24) provided the opportunity to use DNA microarray 
technology to detect large sequence polymorphisms (LSPs). LSPs provided deep evolutionary 
understanding of the members of MTBC. Currently, seven distinct phylogeographical lineages of 
MTBC have been identified namely; Indo-oceanic (Lineage 1), East-Asian (Lineage 2), East-African-
Indian (Lineage 3), Euro-American (Lineage 4), West African lineage 1 (Lineage 5), West African 
lineage 2 (Lineage 6)-lineage 5 and 6 are of M. africanum species, and lineage 7 mostly located in 
the Horn of Africa (25-27). Lineage 1 and 3 are restricted to South East Asia, Central and South Asia, 
and Africa. Lineage 5 and 6 are also restricted to Western parts of West Africa with lineage 6 
dominating Western part while lineage 5 dominates East-region bordering Gulf of Guinea. Lineage 
2 (includes the Beijing family) predominates East Asia, Central Asia, Russia and South Africa while 
Lineage 4 frequently occurs in Asia, Europe, Africa and America. It’s still unknown why some 
lineages are restricted in certain geographical locations. Social factors and differences in host-
pathogen compatibility or local adaption are thought to be the drivers of lineage-specific associations 
with certain particular human populations (25). Alternatively, some of the geographically restricted 
genotypes are thought to have emerged recently in populations with limited  mobility hence have had 
insufficient time to spread globally (28). Conversely, lineage 4 is the most widespread cause of TB 
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globally and its dissemination may be attributed to the success of international travel by people from 
Europe and America (28).  
MTBC strains display low genetic diversity and no distinct evidence of lateral gene transfer (LGT) 
since the complex is thought to have rose from a single clonal expansion (21). This is hypothesized 
to be due to loss of molecular mechanisms required for LGT or lack of opportunity to carry out LGT 
due to the nature of its life cycle. Low genetic diversity is consistent with pathogens emerging from 
a genetic bottleneck and within MTBC, the relative lack of sequence diversity is consistent with a 
bottleneck at the split between the MTBC and the progenitor population (21). Patterns of clonal 
expansion from a recombinant progenitor have been observed among Mycobacterium avium, which 
is related to Mycobacterium tuberculosis (29). This could suggest that within Mycobacteria, there 
could be a potential common constraints in evolution either as they adapt to the host or as a 
consequence of their pathogenicity (21). There some evidence of recombination within 
Mycobacterium canettii and its other members which can’t be explained (30).  
 
Figure 1.5: Evolutionary relationship between selected mycobacteria and members of the 
Mycobacterium tuberculosis complex. Mycobacteria are predominantly environmental organisms. 
Several transitions from the environment to pathogenicity have occurred in these mycobacteria 
including transitions for Mycobacterium avium and the Mycobacterium tuberculosis complex 
(MTBC). The MTBC was thought to arise as a clonal expansion from a smooth tubercle bacillus 
(STB) progenitor population. The animal-adapted Mycobacterium bovis ecotypes branch from a 
presumed human-adapted lineage of Mycobacterium africanum that is currently restricted to West 
Africa. Human-adapted Mycobacterium tuberculosis strains are grouped into seven main lineages, 
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each of which is primarily associated with distinct geographical distribution. The dates of branching 
events are only crude estimates. TbD1 indicates the deletion event specific for Mycobacterium 
tuberculosis lineages 2, 3 and 4. All species shown are from the genus Mycobacterium (adopted from 
Galagan et al,(21)). 
1.3 Mycobacterium tuberculosis pathogenesis  
Infection with tuberculosis occurs when organisms in an aerosolized environment are inhaled into the 
alveoli of a host (Figure 1.6) (31). The primary outcome is not only disease but containment and 
latency as 90% of people exposed never develop disease (32). With one-third of the world’s 
population estimated to be infected, about 12% immune-sensitised individuals develop the disease 
(33). Disease development is a reflection of the evolutionary strategy by the pathogen towards its 
existence with the human host as it ensures a balance between transmission and not rapidly killing its 
host (34). Studies have been undertaken to understand the role played by individual host factors to 
contribute to TB susceptibility but verification of the proposed mechanisms in different global human 
populations have not been achieved (35, 36). Understanding the extent of Mycobacterium 
tuberculosis adaptation to human host still remains to be fully elucidated.  
There are two major forms of tuberculosis: respiratory disease (affecting the lungs) and non-
respiratory (affecting other parts of the body). As an intracellular pathogen, it’s primarily located in 
the alveolar macrophages during respiratory disease. During lung infection, series of complex 
interactions with host immune system occurs including delay in onset of adaptive immunity, more 
macrophages, neutrophils and specific T cells are recruited to the infection site to form a granuloma 
(34). The pathogen is postulated to be unable to multiply within the granuloma because of its acidic 
environment and low oxygen concentration. However, recent advances in zebra fish live imaging 
research suggest that the granuloma offers a protective niche that enables pathogen replication (37). 
The fate of individual’s granuloma is thought to depend on local host factors like inflammation (37) 
where too much local inflammation leads to granuloma necrosis hence providing a rich source of 
infectious organisms for transmission. Uncontrolled liquefaction of granulomas is associated with 
extensive lung damage that ultimately causes death by suffocation due to insufficient oxygen. The 
pathogen can also spread to other parts of the host tissues via the lymphatic system, through blood to 
organs like brain (tubercular meningitis) liver, spleen (miliary tuberculosis) and pleural space (38). 
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Figure 1.6: Natural development of tuberculosis. Small droplet nuclei (1-5µm) containing 
Mycobacterium tuberculosis are deposited in the alveoli (1) where host-pathogen interactions occur. 
70% of individuals exposed do not get infected (2) where 30% develop infection (3). Infection is 
contained in 90% of those infected (latent) (4). The remaining 10% will develop progressive primary 
tuberculosis (5). During this phase, extensive lymphohaematogenous dissemination (6) to various 
organs can result in military tuberculosis. People with latent tuberculosis infection have a 10% 
lifetime risk of reactivation of infection, resulting in post-primary tuberculosis (7). 50% of re-
activations occur during the first 2 years of primary infection. By contrast, in HIV-infected 
individuals with latent infection, the risk of re-activation is enormously high (approximately 
10%/year). Massive lymphohaematogenous dissemination during re-activation (8) can result in 
military tuberculosis (progressive post-primary military tuberculosis). In areas with high transmission 
rates, re-infection with a new strain of Mycobacterium tuberculosis (9) can occur and the cycle is 
repeated. *Important in endemic areas. MTB-military tuberculosis, TB-tuberculosis, TNF-tumour 
necrosis factor (adopted from Sharma et al,(31)).  
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1.3.1 Diagnosis of latent tuberculosis infection 
Diagnosis of latent tuberculosis infection (LTBI) generally depends on the immune responses to 
tuberculin skin tests (TSTs) or interferon-gamma (IFNγ) release assays (IGRAs). TST is based on the 
fact that infection with Mycobacterium tuberculosis produces a delayed-type hypersensitivity skin 
reaction to certain components of the bacterium (purified protein derivative, PPD). While IGRAs are 
based on the fact that T-cells from people infected with Mycobacterium tuberculosis become 
sensitised to ESAT-6 or CFP-10 in vivo and release IFNγ when they re-encounter the same antigens 
ex vivo (39). If the pathogen is eliminated by the host innate immune response, then TSTs and IGRAs 
might be negative but by adaptive immune responses, TSTs and IGRAs might be positive or negative 
depending on whether memory T cell responses are primed (40). With availability of commercial 
immunodiagnostic tests, close contacts of index cases, immune-compromised persons and recent 
immigrants are recommended for LTBI testing (41). These groups are at risk of progressing from 
LTBI to active disease hence receiving LTBI treatment could prevent it. WHO guidelines advocate 
for exclusion of active tuberculosis and recommend chemoprophylaxis on the basis of TST or IGRAs 
results in low-burdened settings (42). In close contact cases, individually tailored regimens are 
administered (based on the drug susceptibility profile of the index case) especially when benefits 
outweigh harms like for children <5 years (42). Although a few studies have reported TST and IGRA 
tests to have reduced sensitivity especially in immune-compromising conditions like HIV co-
infection and low predictive value for progression to active TB (43), there is a continued need to 
screen LTBI in high-risk individuals.  
1.3.2 Vaccination 
Globally, >90% of newborns are annually immunized against active tuberculosis disease using the 
M. bovis Bacilli Calmette-Guérin (BCG) vaccine (44). The live attenuated vaccine was produced in 
1921 by Albert Calmette and Camille Guérin and that process involved culturing M. bovis in bile for 
13 years, passaging every two weeks for a total of 230 passages. During this time, the virulence of 
the passaged strains was measured in different animal species that included guineapigs, rabbits, dogs, 
cows, horses, monkeys and unidentified humans; all showing progressive decrease with continued 
passaging (45). In clinical trials, the efficacy of the BCG vaccine against pulmonary TB in adults has 
been reported to be 0–80% with some settings like South India showing no protection (46). The 
reasons for this observed variability in efficacy are unknown however, one study noted higher 
protection from individuals residing further away from the equator (47). It is unclear how greater 
efficacy at higher latitude is obtained, it may depend on exposure to non-tuberculous mycobacteria, 
to Mycobacterium tuberculosis or on other still undefined causative factors. Case–control studies in 
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infants and children <5 years have found the efficacy of the BCG vaccine to protect against severe, 
extra-pulmonary TB disease, to be between 50%-80% while against pulmonary TB disease is thought 
to vary (40, 48).  
Development of effective TB vaccine is hindered by various factors including; failure to understand 
the complexity of the biology, poor correlation of efficacy between animals and human beings and 
limited funding for clinical trials (49). There is a variety of unknown host specific factors that can 
impact on the response to a vaccine and interfere with its efficacy e.g. the recent identified 
unconventional T-cell responses such as CD1, MR1, HLA-E and γδ T-cells on BCG vaccine (50). 
Such limited gaps of knowledge lead to failures of new vaccines hence low commercial value which 
make the process of developing the vaccines unattractive to investors/industry (49). Several 
alternative approaches and vaccine concepts are being investigated including clinical trials and 
challenge models that include humans, interrogation of infectious dose, use of non-protein antigens, 
and identification of alternative components of the immune system that might be relevant to host 
immunity (e.g. innate and regulatory components, re-visiting the role of antibodies in protection) (34). 
Presently, there are several vaccine candidates designed to either replace BCG as pre-exposure 
vaccines, given at infancy or adolescence to augment BCG-mediated protection (prime–boost 
strategy) or to shorten or potentiate treatment (therapeutic vaccine) (51). Such categories of vaccines 
include live attenuated Mycobacterium tuberculosis, re-engineered BCG, mycobacterial proteins 
expressed through a viral vector or plasmid DNA, mycobacterial whole cells or extract and adjuvant-
complex single or fusion tuberculosis-specific proteins (49). New knowledge of host-pathogen 
interactions is currently needed to facilitate development of new vaccines required to eradicate TB 
disease.   
1.4 Diagnosis of active tuberculosis 
Four main technologies are currently used for detection of active TB disease: imaging techniques 
(chest X-rays and positron emission tomography-computerized tomography), microscopy (sputum 
smears), culture-based methods and molecular tests.  Global diagnostic capacity is low with sub-
optimal case detection rate of 67%. Therefore there is an urgent need to scale up case finding (1). 
Tests that are community-based, sensitive, low-cost, user-friendly, high throughput with same-day 
turn-around time are urgently needed (52). Additionally, these tests should be able to diagnose extra-
pulmonary tuberculosis since it makes up 15% of global TB burden (34). A number of technologies 
detecting different biomarkers in saliva, blood, urine or sputum are commercially available while 
others in developments (Figure 1.7) (53). 
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Figure 1.7: Pipeline of commercially available and fast follower molecular diagnostics for 
tuberculosis depending on the level of the health care facility where they are deployed (reference 
laboratory, district/intermediate level and peripheral microscopy centre) (adopted from unitaid  
report, 2016(53)) 
Smear microscopy, despite its suboptimal sensitivity estimated (limit of detection of ~10⁴ organisms 
per mL) in comparison to culture, is the most routinely used mycobacterial diagnostic test in low and 
middle-income countries (54). Due to its low implementation/maintenance cost, ease of use and quick 
result turn-around time (same day), light-emitting-diode (LED) microscopy was endorsed and 
recommended by WHO in 2009 as one of the diagnostic tool for TB diagnosis (55). Same day 
microscopy (two specimens collected at the spot visit) is highly recommended for a quick turn-around 
time (54). Sample centrifugation combined with fluorescence microscopy has been shown to improve 
sensitivity by 10% in comparison to ZN direct smear microscopy (56). 
 
Solid culture was the first method used for primary isolation of MTBC from clinical specimens (57). 
There are two main solid culture media, the egg-based media such as Ogawa, Lowenstein Jensen (LJ) 
and the agar-based media such as Middlebrook 7H10 and 7H11. Some of the advantages of agar-
based over egg-based media include no need for drug-free eggs and an inspissator, growth appears 
faster, easy to visualize and separation of individual colonies with larger transparent surface and their 
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larger surface area makes it easier to recover MTB in the presence of contaminants. Furthermore, 
antibiotics which do not inhibit the growth of MTB can be incorporated into the agar media to 
suppress contaminant growth and make the media selective for MTB. There is no general agreement 
on which solid medium is most reliable for isolation of MTB, so the choice is based on personal 
experience, laboratory tradition, or both  but egg based media is easier to make and cheap (58). 
                                                                                                                                                                                                                                                                                                                                              
Liquid culture like the Mycobacteria Growth Indicator Tube (MGIT) systems are now the gold 
standard for the diagnosis of tuberculosis as they offer a faster turn-around time and have a 10% 
greater yield than solid media. They include the automated and manual systems. In 2007, MGIT 
systems were recommended by WHO to be used in combination with MPT64 antigen-based species 
confirmatory tests for diagnosis and drug susceptibility testing (DST) in low-income and middle-
income countries (59). However, liquid culture systems are expensive and prone to contamination. 
Alternative inexpensive noncommercial culture and DST methods were endorsed by WHO in 2009 
for use as an interim solution in resource constrained settings and these included microscopically 
observed drug susceptibility (MODS) and the nitrate reductase assays (59).  
 
There is a variety of commercial molecular-based confirmatory tests that include nucleic acid 
amplification tests (NAATs) which have potential to replace microscopy as they offer faster, effective 
diagnosis and some include testing for drug resistance. In 2015, WHO recommended the use of lateral 
flow (LF) strip-based immunodiagnostic assay for detection of lipoarabinomannan (LAM) antigen in 
urine as a rapid diagnosis of TB (60). This test has potential to replace smear microscopy especially 
among HIV co-infected people but there is need for more population studies. Loop-mediated 
isothermal amplification (TB-LAMP) assay is another low complexity NAAT-based test, designed 
to be used in high-burdened settings and was endorsed by WHO in 2016 (61). It’s used to diagnose 
TB direct from sputa but just like the previous test, there is need for more population studies. To 
enhance capacity for rapid diagnosis of drug resistant tuberculosis; in 2015, WHO updated a policy 
for use of two commercial line probe assays (LPAs) for the rapid molecular detection of drug 
resistance in smear-positive specimens or culture isolates. These were Hain Lifescience (Germany) 
Genotype® MTBDRplusv2.0 and the NIPRO corporation (Japan) NTM+MDRTB detection kit 2 (53). 
In 2010, WHO endorsed another NAAT assay known as Gene Xpert MTB/RIF (Cepheid, Sunnyvale, 
CA, USA) that uses a series of molecular probes and real-time PCR technology to detect 
Mycobacterium tuberculosis and rifampicin resistance (62). The cartridge-based system dispenses the 
need for sputum to be processed in advance, needs minimum laboratory expertise hence utilized 
outside a reference laboratory, and quick turnaround (results available in less than 2hrs). The 
redevelopment of the cartridge and assay designs has resulted in Gene Xpert MTB/RIF Ultra that has 
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a limit of detection (LOD) of 16 bacterial colony forming units (cfu) per ml compared to 114 cfu/ml 
in Gene Xpert MTB/RIF (63). A recent multi-national study reported a comparison performance 
between Xpert MTB/RIF and Ultra on sputa from 1753 patients with Ultra having a higher overall 
sensitivity (88%) than Xpert (83%) (64). But ultra’s improved sensitivity was however, associated 
with a 2% lower specificity than Xpert (96% [94–97] vs 98% [97–99]) and this was attributed to the 
excess detection of DNA from non-viable Mycobacterium tuberculosis especially from previously 
treated patients. It’s not yet known how ultra will perform among extra-pulmonary samples especially 
from pericaridial, pleural or abdominal tuberculosis since Xpert previously didn’t perform well (65, 
66).  
 
1.4.1 Treatment of tuberculosis 
The main objective of TB treatment is to rapidly kill the MTB bacilli hence cure the patient and 
improve quality of life, prevent the emergence and development of drug resistance, prevent relapse 
and stop transmission. Early experience in clinical trials demonstrated that multiple agents are 
necessary to prevent the emergence of a drug-resistant population as a consequence of selection 
pressure from administration of a single drug (67). The current preferred regimen for active drug-
sensitive TB disease is a minimum of 6 months of therapy with rifampicin, isoniazid, pyrazinamide 
and ethambutol during the first 2 months (the intensive phase of treatment) followed by isoniazid and 
rifampicin for 4 months (the continuation phase) (Table 2). The choice of regimen depends on the 
primary resistance to anti-TB drug, site of infection (Pulmonary/Extra-pulmonary), immunological 
status (HIV co-infection) and economic resource for treatment. Treatment efficacy and progress are 
usually monitored with repeat sputum smears, cultures and chest X-rays. Although the regimen has 
an estimated success rate of 86% (1), it has limitations especially with the long duration on therapy 
that increases chances of defaulting especially after 4 weeks of treatment (7%-53%) (68). Adverse 
side effects like increased levels of liver enzymes, skin rash, gastrointestinal intolerance, neuropathy 
and arthralgia are reported in some patients.  
Directly observed therapy (DOT) is widely implemented by tuberculosis control programs to improve 
adherence and reduce default. In 2013, a meta-analysis study comparing outcomes of DOT with self-
administered therapy reported no difference in cure, relapse, or acquired drug resistance but noted 
decreased proportion of patients defaulting therapy when on DOT (69). WHO no longer recommends 
universal DOT and encourages a flexible approach to supervision of treatment in health-care 
facilities, workplace, or community with an exception of selected populations (e.g. injection drug 
users and prisoners) for whom DOT is still recommended (70) 
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1.4.2 Treatment of drug resistant tuberculosis 
WHO defines multidrug-resistant (MDR) tuberculosis as resistance to at least isoniazid and 
rifampicin when first-line therapy is unlikely to cure the disease and switch to a second-line drug 
regimen. Similarly, extensively drug-resistant (XDR) tuberculosis is MDR tuberculosis that is 
resistant to fluoroquinolones and any second-line injectable drugs, indicating the probable failure of 
the standardized second-line treatment regimen. Drug resistance in TB is a growing global threat with 
490,000 new cases of MDR-TB estimated to have occurred in 2016, and the highest proportion noted 
from India, China and Russian Federation (1). Australia is estimated to have had 21 MDR cases and 
1 XDR while Papua New Guinea is one of the high burdened-MDR TB countries with estimates of 
more than 1000 MDR cases notified in 2016 (1). 
 
Early, rapid diagnosis and timely initiation of an effective regimen against active drug-resistant TB 
disease is essential for optimizing treatment outcomes, minimizing disease transmission and reducing 
further drug resistance. The scarcity of comprehensive and rapid susceptibility tests directly from 
sputum means that empirical regimens are still frequently used. Designing an appropriate regimen is 
a complex task as it depends on the characteristics of the patient (HIV infection, diabetes, pregnancy, 
and age) and the specific drug susceptibility profile of the organism (40). The current therapies are 
lengthy (>18months for MDR cases), have uncertain efficacy, higher toxicity and are based on poor 
evidence. Treatment success rates in many endemic countries is estimated to be around 50% and this 
has led to decentralized treatment in these countries for better treatment outcomes (71). Emergence 
of incurable tuberculosis (XDR tuberculosis failures and resistance beyond XDR tuberculosis), totally 
drug-resistant (TDR) tuberculosis is well documented in many countries like India, Russia and South 
Africa (71). Community-based transmission of untreatable strains has raised legal, ethical, and 
logistical dilemmas about placement of patients and their rights to unrestricted travel (72). 
 
WHO recommends use of a conventional regimen that consists of at least five drugs that include 
pyrazinamide and four core second-line drugs for treatment for rifampicin-resistant tuberculosis or 
MDR (73). This approach is estimated to be effective at approximately 50% of MDR tuberculosis 
treatments (74). Nevertheless, some of the drawbacks include toxicity, pill burden, poor adherence 
and 6–8 months of painful injections with second-line injectable drugs. In 2016, WHO recommended 
a standardised shorter MDR tuberculosis treatment regimen that had a 90% treatment success rate on 
MDR-naive patients from 14 different countries (75). The shorter MDR tuberculosis regimen (9–12 
months) includes three drugs (kanamycin, prothionamide, and high-dose isoniazid) for 4–6 months, 
with additional drugs (moxifloxacin, clofazimine, pyrazinamide, and ethambutol) given throughout 
treatment. Although there is an urgent need for new drugs, the process of drug development is long 
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and expensive hence attempts to use intermittent regimens or existing anti-TB drugs that were never 
widely prescribed or higher doses of currently used anti-TB drugs and ‘re-purposed’ drugs could 
assist in treatment (72).  Some of the re-purposed drugs like clofazimine and linezolid are showing 
great potential for treatment of drug-resistant tuberculosis as they are being tested in various clinical 
trials (76, 77). Bedaquiline is a new oral diarylquinoline drug developed for tuberculosis that inhibits 
the Mycobacterium tuberculosis ATP synthase and in preclinical testing, bedaquiline plus 
pyrazinamide had better sterilising activity than rifampicin, pyrazinamide and isoniazid (78). After 
approval by US Food and Drug Administration in 2012, bedaquiline is a new drug (first in 40 years) 
with novel mechanism of action that recently had WHO issue an ‘interim policy guideline’ for its 
safe use (79). WHO recommends bedaquiline to be given for 6 months in treatment of MDR TB adult 
patients who don’t have other treatment options (79). Another new drug for treatment of drug resistant 
tuberculosis is Delamanid; a pro-drug that is activated by an F420-dependent mycobacterial 
nitroreductase and is active against dividing and non-replicating bacilli (74). There is continued effort 
to develop more new drugs that could lead to construction of better regimens with less side effects 
like injection-free regimens. 
 
1.4.3 Mechanism of drug resistance  
Resistance in MTB is almost exclusively caused by spontaneous chromosomal mutations (deletions, 
insertions, substitutions, alteration/loss of RNA/ protein function) in genes encoding drug targets or 
enabling enzymes (80, 81). Resistance conferring mutations in target genes exist among wild type 
strains at a frequency of 10-3 to 10-9 thus monotherapy kills all the susceptible bacilli but the resistant 
bacilli continue to grow replacing the susceptible ones (82). MTB is thought to have a low mutation 
rate (0.3-0.5 substitutions per genome per year) but resistance to antibiotics rises quickly (83, 84). 
This is so because of the number of mutations that confer resistance depend on the intrinsic mutation 
rate, the large bacterial population within an individual, fitness effect of the mutation and mechanisms 
of action by the target drugs (28). Sequential mutations in additional genes can lead to resistance to 
additional drug targets hence emergence of strains resistant to multiple drugs. The order in which 
resistance is acquired might be reflected by the number of different mutations that lead to resistance 
to a specific drug and the relative fitness costs associated with the specific mutations in absence of 
the drug (e.g. some mutations might lead to less successful survival and reproduction of the organism) 
(80). Mutations that lead to resistance can be deleterious and produce a fitness cost hence 
hypothesised to be less virulent or transmissible than drug-sensitive strains. Additional mutations 
often follow or coincide with drug resistance mutations and these can compensate for deleterious 
effects e.g. De Vos et al identified putative compensatory mutations in rpoC gene of rifampicin-
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resistant MTB associated with ongoing transmission (85). This illustrates the epistatic interactions of 
different genes involved in drug resistance 
 
Table 1.2: Important first line, second line and third anti-TB drugs used for susceptible and 
resistant tuberculosis 
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MTB also possess intrinsic drug resistance mechanisms attributed to its mycolic acid containing cell 
wall giving low permeability to many antibiotics and other therapeutic agents (86). Within the cell 
wall and cell membrane are natural efflux pumps responsible for resistance to tetracylines, and some 
fluoroquinolones and aminogylcosides (87). It’s thought that during bacterial stress reaction to the 
suboptimal antibiotic concentrations and monotherapy, efflux pumps in the bacilli are unregulated 
allowing for development of mutations in the canonical drug resistance genes. This effect is 
demonstrated by low-level resistance that is reversed by efflux pump inhibitors (88). Besides the 
permeability barrier, the bacteria also possess β-lactamase enzymes in the cell membrane encoded by 
blaC and blaS genes; responsible for resistance to β-lactam antibiotics (89). The acquisition of drug 
resistance or reactivation of drug-resistant tuberculosis is principally referred to as acquired resistance 
(secondary resistance) while primary resistance (transmitted resistance) occurs when resistant strains 
are transmitted to a new host (73, 74, 90). 
1.5 Current genotyping techniques and their limitations 
Mycobacteria genotyping is an important epidemiological tool used to investigate laboratory cross 
contamination, distinguish strains among two or more patients, strain outbreak investigations and 
disease surveillance. Methods of DNA genotyping have differing strain discriminatory power as they 
offer insights in the global epidemiology and phylogeny of TB. The earlier strain typing methods 
relied on phenotypic characteristics such as colony morphology, susceptibility to anti TB drugs or 
mycobacterial phage typing. Mycobacterial phage typing was one of the first methods that provided 
little insight of strain transmission and had low numbers of recognizable mycobacteriophages (91). 
Such methods were rapidly replaced with more reliable and relatively stable strain genomic markers. 
 
1.5.1 Insertion Sequence 6110-Restricted Fragment Length Polymorphism (IS6110-RFLP) 
typing 
The IS6110 is a mobile genetic element that belongs to IS3 family; 0.8-2.5kb long with unique 28bp 
terminal inverted repeats that encode the transposase enzyme responsible to transposition. 
Differences in the copy number and location in the genome predisposed this sequence to be used as 
an Mycobacterium tuberculosis genotyping marker (92). This method includes digestion of genomic 
DNA with PvuII restriction enzyme that cleaves the IS6110 only once thus generating fragments 
which are separated by gel electrophoresis, transferred to membrane and hybridized for visualization. 
In a national tuberculosis control program (Netherland), this technique used to be utilized as the gold-
standard for MTB typing (93). However, it requires at least 2µg of high quality DNA for restriction 
enzyme digestion and thus requiring time consuming solid culturing for 6 weeks. The discriminatory 
power of this technique is reported to be insufficient especially for strains with low copy number 
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(≤6). Limited discriminatory power of this technique is further proposed by some MTB strains lacking 
the IS6110 mobile element as seen in a San Francisco study of 1569 clinical isolates where 1% of the 
isolates were found lacking the IS6110 sequence region (94). One of the earlier studies that tested the 
resolution RFLP typing found two MTB isolates differing by 130 single nucleotide polymorphisms 
(SNPs) as detected by whole genome sequencing (WGS) but had an identical RFLP profiles (95). 
Since the two isolates had differing resistance profiles, this illustrates the impact of limited resolution 
on clinical relevance of the disease for effective control strategies  
 
1.5.2 Spacer Oligotyping (Spoligotyping) 
Spoligotyping is the first genotypic method used for detection MTB and strain differentiation among 
clinical samples without culture. This method is based on the polymorphism of the direct repeat (DR) 
locus (31 direct repeats) interspersed with unique non repetitive spacer sequences of length 34-41bp 
varying in numbers and presence/absence among strains (96, 97). This genetic variation is thought to 
be brought about as a result of homologous recombination and IS6110 integration (98). The entire 
DR locus is PCR amplified using inversely oriented primers and the PCR products reverse hybridized 
on to a nylon membrane with 43 covalently bound synthetic oligonucleotides representing H37Rv 
spacers (1-19, 22-32, 37-43) and M. bovis BCG spacers (20-21, 33-36) thus different strains giving 
different hybridization patterns. After multiple studies from 122 different countries that had utilized 
this method, an international spoligotyping database (spolDB4) was formed, containing 39,295 
strains and tentatively classified them into 62 clades/lineages (99). This database is important for 
classification, population genetics and epidemiology of MTB strains. There are eight major 
spoligotypes with each associated with prevalence of TB strains in specific geographical continents 
and these include Beijing (50% Far east Asia, Oceania and Russia), Central Asian Strain (CAS) most 
frequent in middle east/south Asia-India, Ghana/Haarlem (Europe, Central America/Caribbean), X 
family (North and central America), East African Indian (Africa, Far East Asia, Middle East and 
central Asia), Latin American and Mediterranean (LAM) located in South America, Mediterranean 
basin and Caribbean basin; T family found in all continent and S family prevalent in Mediterranean 
basin and southern Africa (99). Since this typing method has a relatively shorter turnaround time than 
IS6110 RFLP, it’s used as complementary or superior test to IS6110 RFLP especially if the strain has 
with low IS6110 copy numbers (100, 101).  
 
1.5.3 MIRU-VNTR typing 
Mycobacterial Interspersed Repetitive Units are 40-100bp DNA sequences often found as tandem 
repeats and dispersed in intergenic regions of Mycobacterium tuberculosis complex, with 41 locations 
in the genome. The exact role of VNTR loci in MTB is not well understood as most are located in 
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non-coding regions but for those located in open reading frame, they have proposed functions such 
as source of antigenic variation, regulation of gene expression, differential translation of genes and 
genome organization (102). MIRU have been classified into three major types; type I sequences 
contain roughly 77bp, type II and type III are characterized by a gap of 24bp and 15bp corresponding 
to 3’ and 5’ portions of type I sequences respectively. Twenty four of these locations display 
polymorphisms in MIRU copy number among non-related Mycobacterium tuberculosis isolates. The 
first described VNTRs were 5 major polymorphic tandem repeats (MPTR) consisting of 10bp 
repeated sequences separated by unique 5bp spacer sequences (103). With the publication of 
Mycobacterium tuberculosis H37Rv genome sequence (24), new VNTR elements called 
mycobacterial interspersed repetitive units (MIRU) in 12 loci were initially found to display 
variations in tandem repeat copy number thus selected for MTB genotyping (104, 105). Due to the 
poor discriminatory power of 12 loci MIRU as compared to IS6110-RFLP analysis for MTB isolates 
(106), increase in resolution was expanded to 24 MIRU-VNTR loci (107). This typing approach is 
based on PCR amplification using primers specific for the flanking regions of MIRU locus followed 
by determination of the sizes of amplicons by gel electrophoresis or running multiplex PCR on an 
automated fluorescence based sequencer. With the length of the repeat units known, the amplicon 
sizes reflect the number of amplified MIRU copies reflected through a numeric MIRU-VNTR code. 
The code can be deposited on a global MIRU-VNTRplus database (http://www.miru-vntrplus.org) 
analysis providing high resolution insights into MTB population structure and identification of MTB 
lineages and sub lineages  for epidemiological analysis (108). Data from this technique can provide 
phylogeny illustrating the basic idea of relatedness however, it’s difficult to resolve temporal 
information based on this data. Some of the limitations of this method are; extreme variations 
exhibited by some target loci, the loci constitute 1% or less of the size of the entire MTB genome 
which is unrepresentative for the strain (24). Limited resolution by this technique has been highlighted by 
studies that investigated outbreaks and identified the same MIRU-VNTR profiles but upon applying WGS, 
they were identified not to be outbreaks (109-111). 
1.6 Whole genome sequencing technology 
The order of nucleic acids in polynucleotide chains ultimately contains the information for hereditary 
and biochemical properties within any organism. The conceptual frame work for DNA replication 
and encoding proteins in nucleic acid was solved by Watson and Crick after solving the three-
dimensional structure of DNA in 1953 (112). Efficient methods for DNA sequencing were first 
developed in the 1970s using the Maxam and Gilbert method where radioactively labelled DNA was 
chemically degraded or through a dideoxy chain terminator method employed by Frederick Sanger. 
Improvements in Sanger sequencing included use of Klenow fragment DNA polymerase that lacks 
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5′ to 3′ exonuclease activity and fluorometric based detection method. With these improvements, the 
human genome project was accomplished ahead of schedule using Sanger sequencing (113). Sanger 
sequencing was generally adopted as the ‘first generation’ sequencing technology with its high 
efficiency and low radioactivity use. 
After human genome project, various next-generation sequencing (NGS) technologies (Figure 1.8) 
that share good performance in throughput, read length, applications, cost and accuracy when 
compared to Sanger sequencing were developed (114).  
First, Roche 454 was the first commercially successful NGS platform, later terminated in 2013 due 
to its failure in the commercial market. In principle, the technology was based on measuring 
pyrosphophate synthesis were by ATP sulfurlase converted pyrophosphate into ATP, which was used 
by luciferase as a substrate to produce light which was detected by the sequencer. A sequence was 
inferred by measure of pyrophosphate production as each nucleotide was washed through the system 
(115). Like Sanger sequencing, this technology was based on ‘sequence by synthesis’ technique as it 
required DNA polymerase to guide the direction of action for an observable output. One of its short 
comings was the high error rate in terms of poly-bases longer than 6bp (114).  
 
Second, Sequencing by Oligo Ligation Detection (SOLiD™) technology came into market after 
purchase by Thermo Fisher scientific™ in 2006. In principle, this technology is based on two-base 
ligation sequencing. Within the flow cell, libraries can be sequenced by 8 base-probe ligation which 
contains ligation site (the first base), cleavage site (the fifth base) and 4 different fluorescent dyes 
(linked to the last base) (114). The fluorescent signal is recorded during complementation of the 
probes and the template strand, and it vanishes by the cleavage of probes’ at the last 3 bases. One of 
the short comings of this technology was the short read length and longer time to complete a run but 
it had the highest base accuracy estimated at 99.85%.  
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Figure 1.8: Examples of high-throughput sequencing platforms and their associated methods of 
library preparation (adopted from Loman et al,(116)) 
 
1.6.1  Illumina sequencing technology 
 
The third technology is Illumina, which has dominated the NGS market and it was utilized in two 
chapters of this thesis. 
Initially known as Solexa and later purchased by Illumina™ in 2007, this technology also adopted 
the ‘sequencing by synthesis’ approach where a polymerase is used to synthesise a complementary 
strand to the single stranded target DNA with terminator nucleotides used to halt the synthesis. 
However, chain termination is not permanent since the terminators used are reversible hence every 
nucleotide is detected as synthesis takes place. The nucleotides are fluorescently tagged for easy 
detection. To prepare a ‘library’ for a target DNA, genomic DNA is first fragmented using an 
exonuclease or by use of a sonicator or nebuliser to produce fragments within a specific size range. 
Adaptors are attached to the fragments which serve four functions: ligation to the flowcell, as primers 
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for PCR amplification, sequencing primer binding sites and as index tags to allow multiplexing of 
multiple libraries in a single run. After adaptor ligation a PCR step is then typically used to enrich 
DNA fragments with the adaptors in the correct orientation. The DNA is then denatured to produce 
single strands, which are then ligated to a flowcell, where each fragment is amplified to form clusters 
of clonal DNA which will increase the intensity of the fluorescent signal. The sequencing reaction is 
carried out with modified versions of the four nucleotides (dATP, dGTP, dCTP, dTTP), each having 
a different cleavable fluorescent dye and blocking group. These allow the reaction to proceed one 
base at a time controlled by cleavage of the blocking group. When a base is incorporated as 
complementary to the template strand, the fluorescent dye is photographed and then removed. This 
allows sequences of millions of DNA fragments to be determined at once; one base at a time (114). 
Paired end (PE) sequencing allows both ends of the fragment to be sequenced which increases not 
only the amount of data but also the accuracy of the technology. The current advanced bench top 
sequencer, under the Nextseq series produces 120 GB of PE reads while the advanced production 
scale sequencers, NovaSeq system produces a maximum output of 6000 GB of data. There may not 
be a single sequencing error rate for Illumina depending on the experiment, platform, chemistry, or 
read length but it’s estimated to be less than 1%  (114, 116-118). 
 
1.6.2 Nanopore Sequencing 
Oxford Nanopore Technologies™ (ONT) founded in 2012 by Hagan Bayley and Gordon Sanghera, 
started developing nanopore-based DNA sequencing which is currently referred to one of the third-
generation DNA sequencing technology. This technology offers high throughput, low cost, label-free 
input material, simplified experimental processes, short turn-around time and longer reads when 
compared to non-nanopore DNA sequencing technologies (119). DNA is sequenced through a pore 
by depolymerisation instead of polymerisation which is carried out by the non-nanopore sequence 
technologies. In principle, application of external voltage makes particles with sizes slightly smaller 
than the pore size to pass through a pore. So nanometer sized pores either embedded in a biological 
membrane or formed in solid state films are placed into cis and trans compartments containing 
conductive electrolytes. Application of a voltage causes the electrolytes to move through the pore 
electrophoretically thereby generating an ionic current signal. When an analyte such as negatively-
charged DNA (in cis chamber) moves through the pore, it interrupts the current signal. Ionic current 
state is resumed after trapped nucleotide entirely squeezes out. Statistical analysis of the amplitude 
and duration of transient current blockades from a translocation event can give physical (size) and 
chemical properties of  the nucleotide (120). There are two main types of nanopores: Biological 
nanopores such as CsgG (from E.coli), α-hemolysin (Staphylococcus aureus), MspA (Mycobacterium 
smegmatis) are usually in lipid bilayers, liposomes etc as transmembrane channels. They are easily 
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manipulated at specific sites (119). Solid state nanopores e.g. graphene and silicon nitride are being 
tested by ONT since they are more stable and have a constant pore size when compared biological 
nanopores (121). 
ONT has three major commercial sequencing platforms; MinION, with an output of 10-20Gb,  
GridION has five MinION flowcells and a more recent PromethION that has 48 flow cells with each 
cell having capacity to run individually or concurrently (122). Besides the portability of the device 
(MinION), the detection of the current signal as the sequencing takes place makes this technology 
ideal for real-time diagnostics in endemic settings. One of the major drawbacks of ONT is the high 
error rate estimated to be 20-35% (123) and there is still on-going research to reduce the error rate. 
Chapter four of this thesis involved use of nanopore sequencing. 
 
1.6.3 Applications of whole genome sequencing to Mycobacteria tuberculosis 
There has been a progressive increase in the number of Mycobacterium tuberculosis WGS projects 
as illustrated by the 42,253 sequence read archives (SRA) deposited in NCBI (as of 15/2/2018). This 
section highlights some of the achievements and challenges from some of the projects.   
 
In 2011, Gardy et al was the first study to utilize WGS as they described the transmission dynamics 
of an outbreak among 32 MTB isolates obtained from a three year period in British Columbia, Canada 
(110). Contact tracing and MIRU-VNTR had suggested a single outbreak but WGS was able to give 
a higher resolution by showing two distinct lineages. They were able to show presence of super-
spreaders (individuals likely to spread the disease to others) within the outbreak. Walker et al 
followed up by showing microevolution of strains within community outbreaks that could not be 
detailed by the conventional genotyping tools (124). They characterized 390 isolates to investigate 
community outbreaks derived from MIRU-VNTR and were able to infer direction of transmission 
through setting an upper threshold of 5 SNPs, identified super-spreaders and estimated mutation rate 
at 0.5 SNPs/genome/year. Other recent studies have demonstrated the advantage of WGS in 
investigating community outbreaks over the conventional methods and this is important for 
optimising local or international control measures (125-128).  
 
WGS provides an opportunity for improved clinical management of drug resistant TB cases by 
providing unprecedented information, including timely phenotypic prediction comparable to the 
current drug susceptibility testing methods (129-131). Identification of structural variants within drug 
target genes have become more reliable in predicting drug susceptibility phenotypes within clinically 
relevant time frame and is financially feasible (129, 132). A multi-national study that compared the 
WGS and routine MTB diagnostic workflows identified WGS to be faster by 9 days in prediction of 
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species, drug susceptibility was £37 cheaper than the present diagnostic workflows (132). A recent 
study utilized DNA extracted from 39 direct patients samples to offer rapid identification and 
susceptibility testing in less than 16 hours at a cost of £96 (133). While detection of mutations in 
genes associated with resistance is simplified by WGS for multiple anti-TB drugs, studies have 
showed an appropriate balance between sensitivity and specificity when using WGS (129, 131). A 
recent study that utilized expert consensus from a global ReSeqTB data sharing platform identified 
286 confidence graded mutations associated with resistance and phenotypic susceptibility (131). The 
study highlighted sensitivity (95% CI) for rifampicin to be 90.3% (89.6–90.9%), 78.2% (77.4–79.0%) 
for Isoniazid while and their specificities were 96.3% (95.7–96.8%) and 94.4% (93.1–95.5%), 
respectively. Second-line drugs had varied sensitivity, 67.4% for capreomycin, 88.2% (85.1–90.9%) 
for moxifloxacin while the specificity ranged from 90.0% (87.1-92.5%) for moxifloxacin to 99.5% 
(99.0–99.8%) for amikacin. This illustrates the power of WGS in relation to DST and provides a 
template for use of precise predictors of drug resistance in clinical decision-making especially during 
formulation of regimens for TB patients. 
 
Because of the large amount of data provided by WGS, there is a significant progress in our 
understanding of the complexity and multifactorial processes involved in antibiotic resistance. One 
of the first aspects learnt through WGS was evidence of compensatory mutations in the RNA 
polymerase genes of rifampin-resistant MTB isolates (134). These mutations have been shown to 
abrogate the negative effects of resistance mutations hence restoring fitness and giving selective 
advantage over drug susceptible counterparts (135). Another form of compensatory mutation has 
recently been described as it was found to restore susceptibility to fluoroquinolone resistant strains 
especially with gyrA mutations (136). Furthermore, knowledge about possible aspects that contribute 
to drug resistance were expanded through identification of mutations within genes or inter-genic 
regions that are under convergent evolution which could confer selective advantage in presence of 
drugs (137). Another recent study by Coll et al applied genome-wide association study (GWAS) 
approach to analyse 6,465 MTB clinical isolates from more than 30 countries (138). They established 
new epistasis relationships among resistance associated genes and identified additional resistance-
associated genes, novel mutations to drugs such as cycloserine, para-aminoslicyclic acid and 
ethionamide, efflux pumps. These provide new targets for molecular diagnostics and development of 
therapeutics against resistant MTB strains.   
 
WGS has also provided a system for differentiating clinical isolates into major lineages and sub-
lineages by using a nomenclature framework which paves way for further investigations into lineage 
or sub-lineage specific pathobiological characteristics (139). Understanding of lineage is of 
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importance to tuberculosis control as it has been shown that strain type may play a role in disease 
outcome, clinical presentation, transmission, variation in vaccine efﬁcacy and emergence of drug 
resistance (140). Coll et al proposed 62 SNP based markers to accurately and discriminatively classify 
the current circulating strains (139). Lineage 4 which is considered to be globally diverse was recently 
identified to have further different sub-lineages based on specific SNPs that were identified from 500 
WGS dataset (141). Some studies have utilized WGS to further reconstruct the bio-geographical 
structure and evolutionary history of globally distributed lineage associated with drug resistance (142, 
143). Merker et al detected an increase in the population of the Beijing sub-lineage for the last 200 
years and associated its success to its virulence and positive selection of mutations (142).  
 
Since WGS requires amounts of MTB DNA for sufficient template for WGS, majority of projects 
have utilized WGS on DNA extracted from cultures.  Few studies have attempted to perform WGS 
on DNA isolated directly from clinical specimens (133, 144, 145). Though there are challenges with 
each of these studies, the approach of WGS from direct samples will have positive impact on clinical 
management of TB patients and control of transmission. The first attempt was by Doughty et al who 
isolated DNA directly from sputum and sequenced it but there was high data contamination with 
human DNA that made drug resistance prediction inadequate (144). The second published attempt 
was by Brown et al. who utilized targeted RNA oligonucleotide baits to capture MTB DNA prior to 
sequencing and obtained good analyzable data but this method was expensive and technically 
demanding for routine use (145). In a recent study by Votintseva et al. demonstrated a rapid and low-
cost DNA isolation method for MTB WGS from direct patient specimens using a mechanical method 
(133). Although the data was sufficient for species identification and drug resistance prediction, there 
was evidence of human DNA contamination that will require further improvement. The authors also 
assessed the performance and turnaround for WGS using Oxford Nanopore based on a single M. bovis 
BCG run to mimic their direct sample DNA isolation protocol and the results illustrated the future 
potential for WGS as a same day test for clinical specimens.  
 
In nearly all of studies mentioned above, approximately 7-10% of the coding genome of MTB was 
discarded during analysis as it encodes genes belonging to the proline-glutamate/proline-proline-
glutamate (PE/PPE) gene families. Members of these gene families are characterized by the presence 
of PE/PPE signature motifs near the N-terminus of their polypeptides (146). Because of their high 
GC content (up to ~85%) and repetitive nature, they are difficult to sequence and analyse especially 
from short read sequencing technology (147). It’s hypothesized that these genes play a role in host 
immune evasion and virulence among the different strains. A recent study utilized one of the largest 
collection of genomes (518) to fully characterize the sequence diversity of PE/PPE gene families 
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across different lineages (148). Although short read sequences were used, they were able to show that 
these gene families vary in a lineage specific manner and illustrated evidence of genetic 
recombination within these genes. As long read sequencing technology becomes more readily 
available and cheap, there is a need to further understand these gene families and assess their impact 
on MTB pathogenesis.  
1.7 Thesis aims 
The overall aim of the thesis was to utilize whole genome sequencing technology to investigate the 
transmission dynamics and evolutionary diversity of strains circulating in the Far North Queensland, 
Australia and Western Province, Papua New Guinea. The following are the specific aims of the 
research exhibited in different chapters: 
 To understand the population structure of strains circulating in a setting of Western Province, 
PNG that are responsible for drug resistance and assess the evolutionary history of the 
dominant strain (chapter two).  
 To assess the possibility of cross-border transmission among PNG patients receiving 
treatment in the Torres Strait Protected Zone (PNG), Australia and evaluate risk factors of 
transmission from both genomic and epidemiological data (chapter three). 
 To assess the utility of Oxford Nanopore Technologies in sequencing of an extensively drug 
resistant strain that is part of a dominant in Western Province, Papua New Guinea, and re-
solving assembly of PE/PPE gene regions (chapter four).  
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Chapter 2: Tuberculosis transmission and emergence of drug resistance in Daru, Western 
Province; Papua New Guinea 
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2.1 Abstract 
An outbreak of MDR TB has been reported on Daru Island, Papua New Guinea. Mycobacterium 
tuberculosis strains driving this outbreak and the temporal accrual of drug resistance mutations have 
not been previously described. Deciphering the evolutionary and molecular basis of drug resistance 
is important for improved TB control and management in this setting.  WGS was performed on 100 
of the 165 clinical isolates referred from Daru General Hospital to the Queensland Mycobacterium 
Reference Laboratory (Supra-National Reference Laboratory), Brisbane during 2012-2015. Ninety 
five isolates were identified to belong to a single modern Beijing sub-lineage strain while five isolates 
were from Euro-American lineage. Molecular dating suggested acquisition of streptomycin and 
isoniazid resistance in the 1960s, with potentially enhanced virulence mediated by a mycP1 mutation. 
The Beijing sub-lineage strain demonstrated high degree of cross-resistance between isoniazid and 
ethionamide (80/95; 84.2%) attributed to an inhA promoter mutation combined with inhA and ndh 
coding mutations. MDR, observed in 78/95 Beijing strains, emerged with the acquisition of a typical 
rpoB mutation together with a compensatory rpoC mutation in the 1980s. There was independent 
acquisition of fluoroquinolone and aminoglycoside resistance; with evidence of local transmission of 
XDR strains estimated to have started from 2009. These findings underscore the importance of WGS 
in informing an effective public health response to MDR/XDR Mycobacterium tuberculosis. 
 
30 
 
2.2 Introduction 
Globally, an estimated 10.4 million cases of tuberculosis (TB) occurred in 2015 and TB caused by 
Mycobacterium tuberculosis (MTB) was the leading cause of death from a single infectious agent 
(149). The emergence and spread of drug resistant MTB strains pose a major challenge to global TB 
prevention efforts (150). Multi-drug resistant (MDR) TB, resistant to at least isoniazid and rifampicin 
accounted for an estimated 480,000 new cases and 250,000 deaths in 2015 (149). Additional 
resistance to fluoroquinolones and second-line injectables  defines extensively drug-resistant (XDR) 
TB (151). In MTB, drug resistance occurs mainly due to the accumulation of chromosomal resistance-
conferring mutations without evidence of lateral gene transfer (152). The emergence of drug 
resistance is dependent on the rate of acquisition of resistance-conferring mutations and the frequency 
with which these drug resistant strains are transmitted especially in communities with inadequate 
treatment or poor adherence (153, 154). Compensatory mutations that limit the fitness cost imposed 
by drug resistance may enhance the clonal spread of the most successful drug resistant strains (154-
156). 
 
Genotyping of MTB using 24-locus mycobacterial interspersed repetitive unit (MIRU-VNTR) 
remains widely used as a primary approach to strain characterization (157). MIRU-VNTR assay 
interrogates a small proportion of the genome with susceptibility to homoplasy and offers a sub-
optimal discriminatory power (158). The discriminatory power of MIRU-VNTR is of particular 
concern with Beijing lineage strains since some of the VNTR loci remain stable through evolutionary 
bottlenecks occurring during transmission events (159, 160). Whole genome sequencing offers 
optimal resolution to explore local transmission dynamics while also revealing the molecular 
mechanisms and evolution of drug resistance (154, 161, 162). 
 
Papua New Guinea has an estimated TB incidence of 432 per 100,000 population (1).  However, the 
reported incidence may be an underestimate for PNG since most rural areas are isolated with limited 
access to proper health services, inaccuracies in census data and variations in population growth 
(163). Daru Island (Figure 2.1) is a 14.7 square km Island with a population of 16,714 (9, 14) and is 
one of the major hotspots for TB outbreaks (164).  The case notification rate in 2016 was estimated 
to be 2901 per 100,000 population (based on 485 cases notified) (14).  A recent national MDR TB 
survey showed that Daru Island had the highest concentration of MDR TB cases in PNG (164), with 
estimates of 0.76% (125 cases) of the population diagnosed with drug resistant TB in 2016 (14).  
However, the MTB strains driving the epidemic on Daru Island, as well as the associated drug 
resistance mutations and temporal accrual of these mutations have not been described.  Surveillance 
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of underlying drug resistance mutations, in addition to routine phenotypic susceptibility testing, is 
important for optimizing TB treatment. In particular, it will help caution the appropriate use of the 
latest as well as re-purposed antibiotics to maximize their effectiveness.  Understanding the evolution 
of drug-resistance is important for evaluating strengths and weaknesses of public health response.  
2.3 Methods 
This was a retrospective study assessing all clinical isolates referred from Daru General Hospital to 
the Supra-National Referral Laboratory (SRL) in Brisbane, Australia over a 29.5 month period 
(October 1, 2012 to March 15, 2015), which had a positive Mycobacterium tuberculosis culture.  
Clinical specimens are routinely referred to SRL for culture and drug sensitivity testing. Criteria for 
referral is on detection of rifampicin resistance by Gene Xpert MTB/RIF assay (Cephid, Sunnyvale, 
California) on a concurrent sample or at the individual discretion of a clinician.   
 
 
Figure 2.1: A Map of Papua New Guinea illustrating the study location of Daru Island –Inset. Daru 
Town is the capital of South Fly district, Western Province of Papua New Guinea (adopted from 
http://d-maps.com) 
2.3.1 Study setting and specimen selection 
Daru Town, located on Daru Island (14·7km2 in area), is the provincial capital of PNG’s Western 
Province and has an estimated population of around 16,714 people (9). Daru General Hospital 
provides health care services to residents of Daru Island and the surrounding mainland communities 
in South Fly District.  
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2.3.2 Study procedures  
DNA was extracted from cultures with confluent growth on Löwenstien-Jensen (LJ) slopes using 
Spin Column High pure PCR template prep kit (Roche Diagnostics, Pennsbury, Germany). MIRU-
VNTR genotyping was performed as per standard protocol (165) and GeneMapper® version 4.0 
(Applied Biosystems, California, USA) was used for fragment analysis.  
Phenotypic drug susceptibility testing to first-line drugs rifampicin (1.0 µg/ml), isoniazid (0.1 µg/ml; 
low-level and 0.4 µg/ml; high-level), streptomycin (1.0 µg/ml), ethambutol (5.0 µg/ml) and 
pyrazinamide (100 µg/ml) was performed based on the proportion method using the automated 
Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 system (Becton Dickinson, New Jersey, 
USA). For MDR TB isolates, susceptibility to the second-line drugs amikacin (1.0 µg/ml), 
capreomycin (2·5 µg/ml), kanamycin (2·5 µg/ml), ethionamide (5·0 µg/ml), ofloxacin (2·0 µg/ml), 
p-aminosalicylic acid (4·0 µg/ml) and cycloserine (50 µg/ml) was determined using MGIT system 
(166, 167). 
DNA for WGS was isolated using a lysozyme-phenol chloroform based method and purified using 
QIAamp DNA mini prep kit (QIAGEN, Hilden, Germany). Paired end libraries were prepared using 
Illumina Nextera® XT DNA library preparation kit and sequenced using the Illumina MiSeq 
sequencing platform (San Diego, CA, USA) at Westmead Institute for Medical Research and 
Australia Genome Research Facility (Sydney, Australia) (raw data available in the NCBI under the 
project file number PRJNA385247). Raw reads were used to derive octal codes using in silico 
SpolPred (168) and spoligotypes inferred using the international database (SpolDB4) (169). Paired 
end reads were quality checked using FastQC v0·11·2 (170), Trimmomatic v0·27 (171) was used to 
remove low quality base pairs (Phred score<30) especially at 3’ ends. Trimmed reads were mapped 
to the H37Rv reference genome (GeneBank: NC_000962·3) using BWA-MEM v0.75 with default 
settings (172). The mean reference coverage was 98·4% (range 96·4-99·8%) and mean high quality 
base coverage was 70.7X (range 25-182X).  
GATK v3.4 UnifiedGenotyper was used to call SNPs and small indels (173). SNPs and small indels 
with at least 10X read depth, 80% allele frequency and with at least 10bp difference between 
neighboring SNPs/indels were retained. Indels of greater than 4bp were excluded from the analysis 
unless occurring within a known drug resistance associated gene. High quality SNPs and indels were 
annotated using SnpEff v4·1 (174) and those in repetitive regions such as PE/PPE were excluded 
from analysis (scripts and command lines available, https://github.com/arnoldbaino/Daru_scripts). 
Mutations in known genes including regulatory genes (Table 2.1) that confer resistance to rifampicin, 
isoniazid, ethambutol, streptomycin, pyrazinamide, fluoroquinolones, amikacin, capreomycin, 
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kanamycin, ethionamide, para-aminosalicyclic acid, cycloserine, bedaquiline, linezolid and 
delamanid were characterized.  
2.3.2.1 Allelic diversity, phylogeny and molecular dating 
The clonal structure from MIRU-VNTR was inferred using a minimum spanning tree algorithm 
implemented in Bionumerics v6·7 (Applied Maths NV, Keistraat 120, Belgium). Data sets from two 
previous independent WGS studies  PRJEB7281 (142) and PRJEB2358 (128); were used as MTB 
global lineage representatives in phylogenetic analysis because they analysed strains from multiple 
countries. Concatenated SNP alignment was used to construct a maximum likelihood phylogenetic 
tree using RAxML v7·4·2; GTRCAT model at 1000 bootstraps (175) and visualized using FigTree 
v1·4·2. 
 
Table 2.1: List of some known resistance conferring genes and compensatory genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular dating of the Beijing outbreak cluster was first performed by Beauti to create an input file 
for BEAST v1·8·2 (176) based on an alignment containing both invariable and variable sites. Base 
substitution was modelled using Hasegawa-Kishino-Yano (HKY) or General Time Reversible (GTR) 
with an estimated base frequency and a gamma distribution among site rate variation with four rate 
categories. The lognormal relaxed clock (uncorrelated) model which assumes independent mutation 
rates on different branches, was used (142, 143, 161, 162). The tree was calibrated using date of 
Drug Genes 
Rifampicin rpoB, rpoC, rpoA, rpoD 
Isoniazid 
fabG1-inhA, inhA, katG, ndh, 
furA, oxyR, aphC, fadE24, 
srmR, kasA, mshA  
Ethambutol 
embB, embC, embA, ubiA, 
embR, iniA, iniC, manB, 
embC-embA 
Pyrazinamide 
pncA, rpsA, panD, Rv2044c-
pncA 
Streptomycin rpsL, gidB, rrs 
Ethionamide fabG1-inhA, ethA, ethR 
Oflocaxin gyrA, gyrB 
Amikacin rrs, whib7, gidB 
Kanamycin Rv2417c-eis, whiB7, rrs, gidB 
Capreomycin tlyA, whiB7, rrs, gidB 
Para-amnosalicylic acid ribD, thyA, dfrA, folC 
Cycloserine  alr, ddl, cycA, ald 
Bedaquiline atpE, Rv0678 
Linezolid rrl, rplC 
Delamanid fgd1, ddn, fbiA, fbiB, fbiC 
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sample collection as tip dates for each genome, specified in years before the present (file used for 
molecular clock analysis is available, https://figshare.com/s/73cfe6062e657419e084). 
Uniform prior distribution for all the trees was utilized using a mean mutation rate of 0.35 
SNP/genome/year (124, 161, 177, 178) and compared the model performance under the different 
demographic models by calculating the Bayes factors from marginal likelihood estimates obtained 
from path sampling/stepping stone sampling (179). For each analysis, two independent runs of 50 
million steps of Markov chain Monte Carlo (MCMC) were performed, discarding 10% burn-in and 
drawing samples at every 5,000 steps. Three independent runs of the best model were performed for 
consistency. Tracer was used to examine Markov chain convergence, adequate mixing, chain length 
and effective sample size (ESS > 200). TreeAnnotator was used to obtain the best supported topology 
under the maximum clade credibility method. 
 
Resistance conferring mutations were parsimoniously mapped on the phylogenetic tree (considering 
no reversion) and divergence time used to infer the likely timing of drug resistance acquisition. The 
number of strains that shared known resistance conferring SNPs from the molecular clock tree nodes 
were enumerated to infer transmitted drug resistance versus non-shared drug resistance conferring 
SNPs (tree branches) to infer acquired drug resistance (154, 162, 180). SeqTrack algorithm (181) was 
used to create transmission networks among the clades. A Fisher’s exact test in R statistical package 
was used to assess the association of observed drug resistance mutations and MDR/XDR phenotypes. 
2.4 Results 
2.4.1 Global phylogeny 
Of 165 Daru isolates collected between 2012-2015, 100 were characterized by MIRU-VNTR and 
whole genome sequenced (Figure 2.2). MIRU-VNTR analysis revealed that 95 isolates formed a 
single dominant cluster (Figure S2-1). Analysis of SNPs derived from WGS revealed all the strains 
in the dominant cluster formed a monophyletic clade in East-Asian lineage (sensu stricto modern 
Beijing lineage), while all the remaining strains belonged to the Euro-American lineage (Figure S2-
2). According to Coll et al classification (139), the modern Beijing lineage was revealed to be Beijing 
sub-lineage 2.2.1.1 while three different sub-lineages were identified among the Euro-American 
lineage (Table S2-1). The Beijing sub-lineage had a median of 23 pairwise differing SNPs between 
samples (range 0-62), highlighting its limited genetic diversity (Figure S2-3).  
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2.4.2 Molecular dating and drug resistance 
A constant demographic model that used GTR substitution and gamma distribution at 4 categories 
was found to be the best fit since it had a better marginal likelihood estimate compared to the other 
models (Table S2-2). Comparison of relaxed molecular clocks was performed in 3 runs with relaxed 
lognormal showing better fit (Table S2-3). The overall mutation rate was estimated to be 0.36 
SNP/genome/per year (95%High Posterior Density, HPD 0.24-0.48) which is consistent with other 
published reports; Bryant et al (0.3 SNP/genome/year) (178), Ford et al (0.4 SNP/genome/year) (177) 
and Merker et al (0.44 SNP/genome/year (142). Table 2.2 summarizes known and new putative drug 
resistance mutations detected within the Beijing sub-lineage, which were parsimoniously mapped to 
a molecular clock phylogenetic tree (Figure 2.3) that identified four clades; A (n=11), B (n=3), C 
(n=60) and D (n=21).  
Diagnostic and follow-up specimens received 
from Daru (2012-2015) that had a positive 
Mycobacterium tuberculosis culture 
165 
Diagnostic specimens with phenotypic DST  
141 
Follow up specimens 
 24  
Culture available for WGS 
116 
WGS successful  
100 
Multiple isolates from the 
same patient 
25 
Failed experiments 
16 
Figure 2.2: Workflow to derive clinical isolates included in the study collected between 1/10/2012 
to 15/3/2015. PNG – Papua New Guinea; SRL– Supra-National Reference Laboratory; DST – 
drug susceptibility test; WGS – whole genome sequencing 
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Figure 2.3: Phylogeny of Beijing sub-lineage strains with dated acquisition of drug resistance 
mutations. With four clades (A, B, C and D) recognizable, colored shapes representing fixed 
resistance conferring mutations for a TB drug or class of TB drug and putative mutations (ndh and 
mycP1) mapped on to tree branches parsimoniously assuming no reversion. Small-red circle-gyrA 
(p.Asp94Ala); hollow-green circle-no rpoB mutation. On the X-axis are colored arrows representing 
the year of drug discovery; black-S (streptomycin, 1946), green-R  (rifampicin,  1966),  purple-I  
(isoniazid,  1952) and  Et (ethionamide,  1956),  blue-E (ethambutol, 1961), brown-P (pyrazinamide, 
1954), red-O (ofloxacin, 1982) and M (moxifloxacin,1996); pink-A (amikacin, 1957) and C 
(capreomycin, 1963) while antigiobram represents in-vitro susceptibility; red squares-resistant and 
blue squares-susceptible.   Branch labels-boot straps 
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Table 2.2: Drug resistance mutations and phenotypic drug resistance observed among Beijing sub-
lineage strains. Aminoglycosides; A-amikacin, K-kanamycin, C-capreomycin. Isoniazidꟷall samples 
with phenotypic resistance had one of the mutations listed. Ethambutolꟷ27/54 samples with one of 
the listed mutations were phenotypically susceptible. Known mutations to Bedaquiline, Delamanid, 
Linezolid and Clofazimine were not identified. *Two dual mutations (p.Ile480Val and p.Ser450Val, 
and p.Gln497Arg and p.Met306Val), **Putative mutation 
 
 
 
 
TB drug Gene Mutation Phenotypically 
resistant (N)  
Phenotypically 
susceptible (N) 
Critical 
concentration 
(µg/ml) 
Rifampicin 
rpoB 
p.Ser450Leu* 78 0 
1 
p.Asp435Val 2 0 
p.Asp435Tyr 2 0 
p.His445Arg 1 0 
p.Ile480Val* 1 0 
p.His445Asp 1 0 
rpoC 
p.Val483Gly 60 0 
p.lle491Thr 1 0 
rpoA p.Val183Gly 1 0 
Isoniazid 
inhA p.Ile21Val 60 0 0.4 
fabG1-
inhA 
C15T 
65 0 0.4 
20 0 0.1 
katG p.Ser315Thr 2 0 0.4 
ndh del, G304** 
61 0 0.4 
2 0 0.1 
Ethambutol embB 
p.Met306Val* 23 21 
 5 
p.Met306Ile 1 1 
p.Gly406Ala 0 1 
p.Gln497Arg* 2 5 
Pyrazinamide pncA 
p.Tyr103Asp 27 1 
100 
p.Trp68Arg 17 0 
p.Thr135Pro 1 0 
p.Gln10Pro 3 0 
p.Asp12Glu 5 0 
Del, gene** 2 0 
Streptomycin 
rpsL p.Lys43Arg 84 0 
8 
rrs A514C 3 0 
Ethionamide 
fabG1-
inhA C15T 80 
2 10 
Quinolones gyrA 
p.Ala90Val 2 0 
2.5 p.Asp94Ala 1 0 
p.Asp94Gly 8 0 
Aminoglycosides 
rrs 
A1401G 1 (A,K,C) 0 
4 
G1484A 1 (K,C) 1 (A) 
G1484T 1 (A,K,C) 0 
tlyA ins397C 3 (C) 1 (C) 
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Strains in clade A were the most distantly and accumulated the fewest drug resistance mutations. 
Clade C demonstrated massive clonal expansion and included the majority of the MDR strains (54 
MDR and 6 XDR). Ten SNPs, including a mutation in mycP1 (p.Thr238Ala) differentiated clade B, 
C and D from clade A (Table S2-4). 
Strains in clades B, C and D demonstrated universal streptomycin resistance conferred by an ancestral 
rpsL (p.Lys43Arg) mutation acquired in the 1960s. The strain ancestral to clade B, C and D also 
acquired an inhA promoter mutation (fabG1-inhA, C-15T) associated with low-level isoniazid 
resistance in the 1960s. The same inhA promoter mutation occurred independently in a single clade 
A strain, while some (3/11) clade A strains acquired streptomycin resistance conferred by an rrs 
(A514C) mutation.  Clade C displayed universal high-level isoniazid resistance potentially conferred 
by an intragenic inhA mutation (p.Ile21Val) acquired in the 1980s. Occasional high-level isoniazid 
resistance in clade B (1/3) and clade D (2/21) strains were not associated with an inhA coding 
mutation while a katG (p.Ser315Thr) mutation was detected in only 2 clade A strains.  
Of the 84 isoniazid-resistant strains tested for ethionamide resistance, 80 (95.2%) were ethionamide 
co-resistant (comprised of 64/67 high level and 16/17 low-level isoniazid-resistant strains).  Of the 4 
remaining ethionamide susceptible strains resistant to isoniazid, 2 have katG mutation but no inhA 
coding or promoter mutations. All strains with cross-resistance to at least low-level isoniazid and 
ethionamide had a fabG1-inhA mutation. I explored the co-occurring mutations observed in these 
strains (Table 2.3).  All strains with co-occurring fabG1-inhA, inhA (p.Ile21Val) and ndh (del.G304) 
mutations were ethionamide-resistant, while 2/3 with both fabG1-inhA and ndh mutations were 
ethionamide-resistant. No other mutations associated with ethionamide resistance, such as ethA or 
ethR were observed.  
 
Table 2.3: Association of isoniazid and ethionamide phenotypes and common genes involved in 
resistance among Beijing sub-lineage strains. INH-isoniazid, ETH-ethionamide. *Observed 
mutations are in Table 1. #high level resistance to INH. A total of 64/67 strains with high-level INH 
were Ethionamide resistant. Three strains (fabG–inhA only) with low-level isoniazid resistance were 
not tested against ethionamide as they were not MDR 
Gene combinations* Total 
High level 
INH 
resistant 
Low level 
INH 
resistant 
Ethionamide 
resistant 
Ethionamide 
susceptible 
fabG1-inhA + inhA + 
ndh 60 60 0 60 0 
fabG1-inhA +ndh only 3 1 2 2 1# 
fabG1-inhA only 22 4 18 18 1 
katG only 2 2 0 0 2 
inhA only 0 0 0 0 0 
ethA only 0 0 0 0 0 
ethr only 0 0 0 0 0 
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Multi-drug resistance was first acquired by clade C in the 1980s with acquisition of a frequently 
encountered rpoB mutation (p.Ser450Leu), together with a compensatory rpoC mutation 
(p.Val483Gly). The ancestral strain in clade B acquired a different rpoB mutation (p.His445Arg) in 
the 1990s without a compensatory mutation. One rifampicin resistant clade A strain acquired a 
different rpoC compensatory mutation (p.Ile491Thr). The majority of clade D strains (17/21) also 
acquired the p.Ser450Leu rpoB mutation, but at a later time point and only one strain had a 
compensatory rpoA (p.Val183Gly) mutation. One rifampicin-resistant clade D strain had two rpoB 
mutations (p.Ser450Leu and p.Ile480Val); confirmed by sequence reads spanning both mutations 
(Figure S2-4). One rifampicin-susceptible isolate in clade D was found to be part of a rifampicin-
resistant clone carrying a common rpoB (p.Ser450Leu) mutation although no mutation was observed 
in this isolate despite adequate sequence coverage (Figure S2-5).  
 
There was poor prediction of ethambutol susceptibility using genotypic, only 50% (27/54) of the 
strains with putative ethambutol resistance-conferring mutations were phenotypically resistant at the 
critical concentration (5.0 mg/L); MIC testing to encompass lower concentrations of ethambutol was 
not performed. The embB (p.Met306Val) mutation first occurred in clade C during the 1980s with 
independent acquisition at later time points in clade A, C and D. Another embB mutation 
(p.Gln497Arg) occurred independently on two occasions in clade C. 
The majority of clade C (53/60; 88·3%) strains had pyrazinamide resistance mutations. The earliest 
mutation pncA (p.Trp68Arg) was acquired in the 1990s. The only two pyrazinamide resistant clade 
A strains shared a 3,990bp genomic deletion (position 2287064-2291054, Figure S2-6) spanning four 
genes including pncA. 
 
2.4.3 Extensively drug resistant TB genotypes 
Fluoroquinolone resistance due to mutations in the gyrA gene was detected in 11/60 (18%) clade C 
strains; 6 were XDR TB (Table 1). A single four-member XDR clone was estimated to have started 
around 2009, characterized by an additional capreomycin resistance mutation (tlyA, insertion C.397). 
One XDR strain with phenotypic resistance to amikacin, kanamycin and capreomycin had both rrs 
(G1484T) and tlyA (insertion397C) mutations, while another with an rrs (G1484A) mutation was 
phenotypically only resistant to kanamycin and capreomycin. (Figure S2-7). The arrangement of 
drug resistance mutations on the tree (Figure 3) together with transmission network analysis of the 
large clades: C and D (Figure S2-8) was used to determine whether MDR/XDR tuberculosis emerged 
because of acquired resistance or direct transmission. Transmitted drug resistance to isoniazid, 
rifampicin, ethambutol and streptomycin was evident in clades B, C and D (P < 0.0001, Table 2.4). 
From transmission network analysis, 6 and 4 distinct clusters (2-4 isolates per cluster) that are tightly 
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linked (<3 SNP difference between samples within cluster) were identified in clade C and D 
respectively (Figure S8).  For the rest of the isolates within the clades, 23 clade C strains (included 4 
XDR) and 6 clade D strains were within 3-5 SNP difference to at least one other isolate reminiscent 
of transmission.  
 
 
 
     
  
C
la
d
e A
 
C
la
d
e 
B
 
C
la
d
e C
 
C
la
d
e D
 
  
  
In
d
ep
en
d
en
t 
C
lu
ster 
C
lu
ster 
In
d
ep
en
d
en
t 
C
lu
ster 
In
d
ep
en
d
en
t 
C
lu
ster 
L
o
cu
s 
rp
o
B
 
1
 
2
 
3
 
0
 
6
0
 
3
 
1
6
 
fa
b
G
1
-
in
h
A
 
1
 
0
 
3
 
0
 
6
0
 
0
 
2
1
 
in
h
A
 
0
 
0
 
0
 
0
 
6
0
 
0
 
0
 
ka
tG
 
0
 
2
 
0
 
0
 
0
 
0
 
0
 
rp
sl 
0
 
3
 
3
 
0
 
6
0
 
0
 
2
1
 
em
b
B
 
2
 
0
 
0
 
3
 
4
6
 
1
 
2
 
p
n
cA
 
0
 
2
 
0
 
0
 
5
3
 
0
 
0
 
g
yrA
 
0
 
0
 
0
 
7
 
4
 
0
 
0
 
rrs 
0
 
0
 
0
 
3
 
0
 
0
 
0
 
tlyA
 
0
 
0
 
0
 
0
 
4
 
0
 
0
 
 
Table 2.4: Frequency of transmitted (cluster) and acquired (independent) drug resistance mutations 
identified in different clades of the Beijing sub-lineage strains inferred from Figure 2.3 
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2.4.4 Resistance among Euro-American lineage 
Of the five identified Euro-American lineage strains (3-Ts, 1-X and 1-Harleem), one isolate (Harleem 
sub-lineage) was identified as MDR. The isolate had Ser450Leu in rpoB responsible for rifampicin 
resistance but with no complimentary mutation in rpoC or rpoA. It also had inhA promoter mutation 
(C15T) for INH and ETM resistance though INH MIC was identified at 0.4mg/µl. Additional 
mutation (p.Pro345Ser) in srmR gene was also identified. Mutation C16T in embA promoter and 
embB, p.Asp328Val were responsible for ethambutol resistance. The isolate was phenotypically 
resistant to PZA and it didn’t have any classical pncA mutation but identified a novel frame-shift 
insertion mutation, Ins47G in pncA gene thought to be responsible for PZA resistance. It also had 
rpsL, p.Lys43Arg mutation for streptomycin resistance and gyrA (p.Asp94His) for fluoroquinolone 
resistance. 
2.5 Discussion 
This was the first study to provide insight into the molecular basis of drug resistance and genealogy 
of the dominant strains circulating in a high prevalent setting on Daru Island in the Western Province, 
Papua New Guinea (PNG). The findings indicate that the large number of MDR TB cases is driven 
by the transmission of a highly drug resistant cluster of a modern Beijing lineage strain. Studies from 
other parts of Papua New Guinea have demonstrated dominance of Euro-American lineage strains, 
(167, 182) although the contribution of Beijing sub-lineage strains may have been underestimated.  
The geographic spread of the Beijing sub-lineage can’t be determined based on the current data, 
however phylogenetic analysis combined with detailed molecular dating suggests that it has been in 
local circulation since the 1940s and first acquired drug resistance mutations in the 1960s. The 
identification of four different clades with distinct evolutionary trajectories suggests a ‘permissive’ 
environment for MTB strains to acquire and spread drug resistance within the study setting.  
 
Clade C was the most successful clade, acquiring resistance to all four first line drugs and 
demonstrated clonal spread of both MDR and XDR strains. Phylogenetic analysis indicated that 
isoniazid and streptomycin resistance were acquired by strains ancestral to clades B, C and D.  This 
is consistent with the use of non-rifampicin containing regimens in the 1960s that were highly reliant 
on isoniazid and streptomycin (183).  Similar analysis done in Russia and South Africa where large 
MDR outbreaks have been recorded also indicated that streptomycin and isoniazid resistance were 
acquired before the introduction of rifampicin containing regimens (154, 161). These settings mostly 
reported high-level isoniazid resistance due to katG mutations. In a recent multinational study, katG 
(p.Ser315Thr) was identified as the harbinger mutation that is most frequently associated with future 
MDR occurrence and risks subsequent clonal spread (180).  
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Beijing strains possessing signature fabG1-inhA (C-15T) mutation that confers low-level isoniazid 
resistance with ethionamide cross-resistance has been observed in South Africa (184, 185). Another 
strain (LAM family) in Portugal had cross-resistance to high level isoniazid and ethionamide 
resistance which was attributed to the double inhA mutations (C-15T and p.Ile21Val) (186). 
Phenotypic drug susceptibility results of clade C strains demonstrated universal high-level isoniazid 
resistance which might be explained by the accumulation of an additional inhA (p.Ile21Val) mutation 
(187, 188).  The double accumulation of mutations may confer high-level isoniazid resistance without 
the fitness cost associated with katG mutations, supporting successful clonal expansion and 
acquisition of additional resistance conferring mutations to other drugs (189). An additional 
consideration is the possibility that the ndh frame shift mutation (deletion Glu102fs) observed only 
in clades B and C may also have contributed, potentially as a compensatory mutation, since SNPs in 
the ndh gene have been associated with increased intracellular NADH/NAD+ ratios hence 
competitive inhibition of activated isoniazid (190). With the recognized description of mutations that 
confer resistance to isoniazid and ethionamide, it is anticipated that the introduction of short course 
regimen for MDR-TB in this setting may prove to be ineffective. This is because the dominant drug 
resistant strain has underlying high-level resistance to two of six regimen drugs, (isoniazid and 
proethionamide-ethionamide analog) due to co-existence of inhA promoter and inhA gene mutations.   
 
The selective advantage of clade C might have been enhanced further by the acquisition of a classic 
rpoB (p.Ser450Leu) rifampicin resistance determining mutation together with a compensatory rpoC 
(p.Val483Gly) mutation that abrogates its negative fitness effects (155). Similar to previous 
observations, (191) one strain had two rpoB mutations of which p.Ile480Val, which lies outside the 
81bp rifampicin resistance determining region, may represent a compensatory mutation. The single 
strain within a clade D rpoB (p.Ser450Leu) cluster, in which were unable to detect an rpoB mutation 
(X75 sequence depth) even though all neighboring strains had the same mutation, may have been due 
to reversion that might have occurred after a transient mutator phenotype. Schmalstieg et al attributed 
this ‘unstable or transient state’ event to be caused sub-therapeutic drug exposures and effects of 
efflux pumps especially in the first steps of acquiring higher level resistance (192). This has never 
been observed in rifampicin resistance and further investigation into the functionality of this aspect 
will help to determine its effects on the development of resistance and transmission. 
 
An effective host immune response is critical to protect individuals against tuberculosis and to limit 
ongoing transmission within communities. The identified putative non-synonymous mycP1 
(p.Thr238Ala) mutation that is ancestral to clades B, C and D. Mouse models used to identify MTB 
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ESX-1 (early secretory antigenic target secretion system 1) substrates and their effects on host cells 
found mycP1 proteins to be essential for early replication in macrophages and contribution to 
virulence by allowing escape of mycobacteria from the phagosome into cytosol of infected 
macrophages (193, 194). Site directed mutagenesis that inactivated mycP1 increased the expression 
of ESAT-6. Altered host immune responses effected by the putative mycP1 (p.Thr238Ala) mutation 
may have increased the virulence and transmissibility of the Beijing sub-lineage strain since the 
observed mutation is within the active site (195), but this remains speculative since clade B 
demonstrated limited clonal expansion. 
 
Previous studies have found a strong correlation between MDR TB and resistance to pyrazinamide 
or ethambutol, which highlights the problem of drug resistance amplification with continued use of 
first-line treatment regimens in patients with undiagnosed MDR TB (196, 197). Our study provides 
evidence that streptomycin resistance in this setting is long standing and, as such, likely provided 
little protection against the development of resistance to first line oral drugs when used in the WHO 
endorsed retreatment regimen, as its potency was compromised by prior treatment.  
There was good correlation between genotypic and phenotypic drug resistance profiles, except for 
ethambutol. This reflects the complex genetic basis of ethambutol resistance, but also emphasizes the 
highly variable results achieved with phenotypic drug susceptibility testing in some strains (162). Safi 
et al. demonstrated the epistatic nature of ethambutol resistance by establishing how mutations in 
embB are often accompanied by polymorphisms in other genes such as nuoD and Rv3806c hence lead 
to progressive increase in the critical concentration (198). Those previous accompanying mutations 
could not be identified in this study, but postulate reduction of critical concentration especially for 
this strain may improve the correlation between resistance phenotype and genotype. Other studies 
have suggested a reduction in MIC to 4.0mg/ml for phenotypic susceptibility of Ethambutol (74, 199) 
 
The manifestation of transmitted MDR-TB and minimal transmission of XDR-TB highlights a 
problem with preventing transmissions. There is need for rapid access to reliable DST and increased 
timely-access to new and repurposed agents such as bedaquiline, delamanid and linezolid containing 
regimen for effective management of MDR/XDR TB. Controlled clinical trials performed in other 
endemic settings like in Russian (200) before roll out of regimens with newer drug agents are required 
in this setting for establishment of minimum number of drugs and duration of treatment that constitute 
an effective regimen. No putative resistance mutations were detected which have been implicated in 
resistance to newer agents. Mutations at rrs position 1484 may affect aminoglycoside susceptibility 
differently, since one XDR sample with an rrs (G1484T) mutation had phenotypic amikacin 
resistance, while another with rrs (G1484A) mutation was susceptible to amikacin. In a systematic 
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review of studies that assessed the use of second line injectables, the rrs (G1484T) mutation was 
described as a specific predictor of injectable drug resistance but not the rrs (G1484A) mutation 
(201). The Hain Genotype®MTBDRsl line probe assay recently endorsed by WHO for rapid detection 
of second-line drug resistance   has a probe for rrs G1484T but may detect G1484A as a failure of 
wild-type binding (202) and hence incorrectly infer resistance to all second-line injectables, which 
could lead to an incorrect choice of treatment. Identification of one MDR isolate out the five Euro-
American lineage strains, which had unique mutations namely Pro345Ser in srmR gene and Ins47G 
in pncA speculated to cause isoniazid and pyrazinamide resistance respectively; highlights another 
threat of drug resistance evolution within this lineage. SrmR gene encodes products which are 
involved in fatty acid biosynthesis and a previous study identified p.Met323Thr mutation to be 
responsible for isoniazid resistance (203). 
 
This study was limited by its retrospective nature and the clinical isolates used failed to capture the 
whole population with MDR TB on Daru Island. Although all available isolates were sequenced, 
unreliable transport for specimens to the reference laboratory resulted in an incomplete sampling of 
MDR-TB during the study period, leading to a modest sample size.  Due to the modest sample size 
and short study period, a fixed mutation rate was used which may have reduced the accuracy of 
evolutionary time point estimates.  Another limitation is the use of sample collection date rather than 
date of diagnosis, although exclusion of follow-up samples should limit the impact of this on 
evolutionary analysis.  Despite these limitations, this study represents the largest drug resistance 
collection from PNG described so far and provides an unbiased view of the evolution of MDR-TB in 
Daru Island.  The estimated dates of divergence are biologically plausible and are temporally 
consistent with respect to introduction of anti-TB drugs on the global market. Unfortunately a detailed 
description of when specific drugs were first used in the study setting was unavailable though it’s 
noted that culture and drug susceptibility testing were started in 2010. There was no availability of 
clinical and epidemiological information to enhance our genomic analysis.  This information is 
critical to identify individuals and population characteristics that facilitate ongoing transmission of 
drug-resistant strains. 
 
In addition, WGS confirmed on-going transmission of drug resistant TB as well as repeated 
acquisition of drug resistance mutations, driven by a modern Beijing sub-lineage strain. A major 
concern is that further spread of the strain to adjacent geographical areas, including the capital city, 
Port Moresby, may amplify transmission within Papua New Guinea. There is urgent need for 
improved early detection of drug resistant tuberculosis cases with linkage to effective care programs 
in order to limit drug resistance amplification and terminate ongoing transmissions. 
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3.1 Abstract 
 
Australia has a very low tuberculosis (TB) incidence while Papua New Guinea’s burden is high. A 
shared open-common border region (Torres Strait Protected Zone –TSPZ) creates a unique 
opportunity for cross border transmission of drug-resistant tuberculosis. WGS was performed on 
strains collected in the TSPZ between 2010-2015 to assess strain diversity, transmission dynamics 
and drug resistance profile. Of the 100 strains sequenced; 79 belonged to East-Asian lineage (sensu 
strico modern Beijing sub-lineage 2.2.1.1) while 21 were of Euro-American lineage (6 different sub-
lineages). Four epidemiologically linked TB cases among Australian residents in TSPZ were 
sequenced and belonged to the same modern Beijing sub-lineage. Only strains from the Beijing sub-
lineage were multi-drug resistant (MDR); typically with high-level isoniazid and ethionamide cross-
resistance and a fabG1 promoter mutation.  With a total of 83 Beijing sub-lineage strains, 33 (39.7%) 
were MDR and 2 (2.4%) were extensively drug resistant (XDR). There was wide distribution of 
strains across the different villages of TSPZ. Transmission network analysis identified genomics 
clusters among strains of the same locality than across localities (P=0.0013). Beijing sub-lineage 
membership was significantly associated with clustering (OR 6.19; 95% CI 2.2-18.07; p<0.001) and 
drug resistance (OR 4.67; 95% CI 1.45-20.9; p=0.019). WGS analysis demonstrated two likely cross-
border transmission events amongst four epidemiologically linked Australian residents with MDR-
TB. WGS demonstrates a pervasive MDR-TB strain has transmitted widely in the PNG villages of 
the TSPZ with demonstrated cross border transmission into Australia.
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3.2 Introduction 
  
Globally, tuberculosis (TB) is the leading infectious cause of death (1), but there is international 
commitment to achieve a 90% reduction in TB incidence by 2035 as part of the ‘End TB 
Strategy’(204). Australia has already achieved ‘pre-elimination’ targets (<10 cases per million 
population) in its non-Indigenous, Australian born population (4). However, achieving TB 
elimination remains a daunting challenge given high population mobility with increased importation 
of TB cases from high incidence settings and cross-border spread from neighboring countries such as 
Papua New Guinea (PNG) (205). In 2013, nearly 90% of TB notifications in Australia were from 
overseas-born persons (4).  
 
The state of Queensland has one of the lowest TB incidence rates in Australia with an estimated 4.0 
cases per 100,000 population (8), while PNG has an estimated TB incidence of 432 per 100,000 
population (206). TB incidence rate in the neighboring Western Province, Papua New Guinea is 
estimated to be 2901 per 100,000 population and its recognized as a major “hot spot” for multi-drug 
resistant (MDR) TB (125 cases in 2016) (12, 164) with conclusive evidence of primary MDR-TB 
transmission(109, 207).  This poses a risk of cross-border TB spread into Australia with subsequent 
establishment of local transmission.  
A Torres Strait treaty signed between PNG and Australia in 1978 created the Torres Strait Protected 
Zone (TSPZ) between the two countries, an area where free cross-border movement (without 
passports or visas) is permitted to carry out traditional customs and economic activities (Figure 3.1) 
(208). The TSPZ includes 13 PNG and 14 Australian Island communities with an estimated 
population of 1526 (209). Regular cross-border movement of people into the TSPZ provides a 
potential route of entry and spread of Mycobacterium tuberculosis (including drug resistant strains) 
into northern Queensland and the rest of Australia. 
 
In 2012, a TSPZ Queensland resident was diagnosed with multi-lobar cavitary pulmonary TB 
resistant to streptomycin only. Following initial improvement with standard therapy, the patient 
deteriorated clinically after 6.5 months of a planned 9 month regimen. Rifampicin resistance was 
detected by Xpert MTB/RIF® assay the following month and MDR-TB was confirmed following 
positive culture and phenotypic drug susceptibility testing (DST). MIRU-VNTR profile of the newly 
isolated strain was different from the initial disease episode and characteristic of TB strains from the 
Western Province, PNG, indicating likely re-infection with an MDR-TB strain (210). This was the 
first documented case of MDR-TB in an Australian resident of the Torres Strait Islands. Three 
additional cases of MDR-TB diagnosed in Australian TSPZ citizens who were current of previous 
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residents of the TSPZ. The four cases were epidemiologically linked through a network of close 
contact as assessed by Communicable Disease Branch (Queensland Health) analysis. At the time of 
diagnosis, two subjects were living in different Queensland cities distant to the TSPZ. Genomic 
relationship between MDR-TB strains was performed as a ‘proof of principle’ for transmission 
through the TSPZ and to geographically distant localities.  
 
 
 
Figure 3.1: A regional map showing location of Islands within the Torres Strait Protected Zone 
between Australia and Papua New Guinea (adopted from Burkhard et al (211)) 
 
The discriminatory power of WGS offers a unique opportunity to delineate TB transmission clusters 
with high resolution when compared to conventional methods of genotyping (142, 143, 160). In the 
previous chapter, WGS was utilized to characterize a large MDR-TB outbreak on Daru Island, the 
administrative capital of the Western Province (PNG), and revealed the dominance of modern Beijing 
sub-lineage dominated on the Island (109). Daru Island is located within the Torres Strait, but not 
within TSPZ. The current study aimed to fill the gap in our understanding of Mycobacterium 
tuberculosis strain diversity within the TSPZ, recognize the extent of spread and identify risk factors 
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for transmission. Accompanied with insights of markers responsible for drug resistance, this study is 
important for improved patient management and to guide public health response in the region. 
3.3 Methods 
3.3.1 Strain selection 
By legislation, all patients diagnosed with TB in Queensland (including PNG residents in TSPZ) are 
supposed to be notified to the Queensland Department of Health. Strains from PNG patients 
diagnosed with TB in the TSPZ between 1 January 2010 and 31 December 2015 were included in the 
study. Detailed documented epidemiological information was unavailable but demographics and 
clinical data was extracted from the Queensland Notifiable Conditions System on 6 April 2016. Four 
cases from Australian residents in TSPZ with strong epidemiological links were also included in the 
study.  
 
3.3.2 Drug susceptibility testing and genotyping 
Mycobacterium tuberculosis culture, species identification, genotyping and direct susceptibility 
testing (DST) were performed at Queensland Mycobacterium Reference Laboratory (QMRL). 
MIRU-VNTR (24 or 15 loci) results obtained as previously described (165) were available for some 
isolates. Phenotypic susceptibility to first-line drugs; rifampicin (1.0 µg/mL), isoniazid (0.1 µg/mL; 
0.1 and 0.4 µg/mL), streptomycin (1.0 µg/mL), ethambutol (5.0 µg/mL) and pyrazinamide (100 
µg/mL) was performed based on the proportion method using the automated Mycobacterial Growth 
Indicator Tube (MGIT) 960 system (Becton Dickinson, Germany). Susceptibility to the second-line 
drugs amikacin (1.0 µg/mL), capreomycin (2.5 µg/mL), kanamycin (2.5 µg/mL), ethionamide (5.0 
µg/mL), ofloxacin (2.0 µg/mL), p-aminosalicylic acid (4.0 µg/ml and cycloserine (50 µg/mL) was 
also determined using MGIT. On a case by case basis, broth micro-dilution method (Sensititre Trek, 
Thermo Fisher Scientific) was also employed to compare DST data with MGIT.  
 
3.3.3 Whole Genome Sequencing  
Mycobacterium tuberculosis isolates were retrieved from -80oC storage, cultured on Lowenstein 
Jensen (LJ) medium for 2-4 weeks and DNA was extracted using an organic-enzymatic based method 
(109). WGS was performed at the Australia Genome Research Facility (AGRF), using Illumina HiSeq 
2000 for paired-end reads of 150-base pairs (bp). Paired end reads were quality checked using FastQC 
v0·11·2 (170) and trimmomatic v0.27 (171) was used to remove low quality base pairs (Phred 
score<30). Reads were mapped to the Mycobacterium tuberculosis H37Rv reference genome 
(GeneBank: NC_000962·3) using BWA-MEM v0.75 (172). GATK v3.4 UnifiedGenotyper (173) 
was used to call SNPs and small indels. SNPs and small indels with at least 10X read depth, 80% 
50 
 
allele frequency and with at least 10 bp difference between neighboring SNPs/indels were selected. 
These high quality SNPs and indels were annotated using SnpEff v4·1 (174). Selected mutations in 
all known genes (including regulatory genes) that confer resistance to TB drugs were assessed as 
previously described in table 2.1. Mutations in repetitive regions such as PE/PPE were excluded from 
the analysis. Raw reads in the form of FASTQ files were submitted to NCBI Sequence Read Archive 
under the project file number PRJNA401368. Scripts for manipulation of raw sequence data are 
available (https://github.com/arnoldbaino/Daru_scripts). 
3.3.4 Phylogenetics and Bayesian coalescent analysis 
Data sets from two previous independent whole-genome sequencing studies, PRJEB7281 and 
PRJEB2358 (128); were used as MTB lineage representatives in phylogenetic analysis. Concatenated 
SNP alignment was used to construct a maximum likelihood phylogenetic tree using RAxML v7.4.2 
(175); GTRCAT model at 1000 bootstraps visualized using FigTree v1.4.2. Molecular dating of the 
Beijing strains was performed using BEAST v1.8.2 (176) as previously described in chapter 2.3.2.1. 
Mutations known to confer resistance first and second line anti-TB medications (including regulatory 
mutations) were parsimoniously mapped onto the resultant tree. 
3.3.5 Transmission assessment  
Pairwise SNP distance (excluding SNPs in known drug resistance genes) between strains was 
calculated using ape library in R statistical package (http://cran.r-project.org/). Performed an 
assessment of SNP difference among the lineages and compared it across the different patient 
localities to set a threshold to be used as a measure of putative transmission. Genomic clusters were 
constructed using median-joining network software namely SeqTrack (181) and Network, version 5. 
The structure of links within clusters assumed the existence of linear transmission among isolates 
from the same locality and putative transmission among isolates from different localities (if the SNP 
difference was within the limit of the threshold). 
 
3.3.6 Statistical analysis  
Patient characteristics were analyzed and compared using the Fisher’s exact test. Univariate and 
multivariable logistic regression analysis were performed to evaluate the relationship between patient 
characteristics and genomic clusters as an outcome variable to infer transmission. All statistical 
analysis was performed using the R statistical package (http://cran.r-project.org/). 
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3.4 Results 
3.4.1 Sample selection 
In total 158 cases from PNG residents in TSPZ were notified with TB during the study period; 131 
(82.9%) had culture confirmed disease. Figure S3-1 reflects the trend in the number of TB cases 
notified during the study period. The sudden decline in cases observed in 2011/12 coincided with the 
time when Australian TB clinics on the outer Torres Islands were ceased and cross-border patients 
referred to enhanced TB services provided on Daru Island. 100 (76.4%) strains were successfully 
sequenced, together with four epidemiologically linked cases among Australians residing or 
previously residing in the TSPZ (Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TSPZ – Torres Strait Protected Zone; WGS-whole genome sequencing, *Inclusive of additional 4 
Queensland resident isolates sequenced, belonging to an epidemiological cluster 
 
3.4.2 Sequencing and phylogeny  
Strains were sequenced using Illumina with mean coverage depth of 74 (range 42-110) and 98.5% 
mean coverage breadth (range 96.3-99.8%). MIRU-VNTR profiles were available for 98/104 patients 
(Table S3-1). Comparison of MIRU profile and pairwise SNP difference revealed a median SNP 
difference of 31 (IQR 24-38) for isolates with the same MIRU profile and median 1101 SNPs (IQR 
All TB cases from PNG residents 
diagnosed in TSPZ (2010-2015) 
158 
Isolates available for WGS 
131 
DNA extracted and WGS 
attempted 
103 
  
WGS successful  
*104 
 
Clinical diagnosis only 
27 
Failed DNA preparations 
28 
Failed WGS quality control 
3 
Figure 3.2: Flow diagram of Mycobacterium tuberculosis strains included in the analysis 
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1066-1119) for isolates with different MIRU profile (Figure S3-2). SNP difference between all 
possible pairs within the dataset was bi-modal with two large peaks representative of the two lineages. 
The possibility of cross contamination among isolates with zero SNP difference was negligible as 
specimens were processed and isolates sequenced on different days. Of the 104 strains sequenced, 
phylogenetic analysis (Figure 3.3) revealed 83 belonged to the modern Beijing sub-lineage 2.2.1.1 
strain, including the four epidemiologically linked Australian MDR-TB strains. Twenty one strains 
belonged to the Euro-American lineage that consisted of 6 different sub-lineages (Table S3-2).  
Although the distribution of the different strains was wide spread among the TSPZ villages, the 
majority (50%) originated from a single PNG village, Mabadauan (Figure S3-3).  
Figure 3.3: Maximum likelihood tree of Mycobacterium tuberculosis strains identified in the Torres 
Strait Protected Zone, compared to lineage representative genomes, rooted on Mycobacterium bovis  
 
 
 
Colour coding of different lineages: yellow-M. bovis; light green- Mycobacterium tuberculosis 
Indo-oceanic; pink-Euro-American; purple-East African-Indian; blue-East Asian. Circle labels-
cross border isolates, star labels-epidemiologically linked Australian isolates, no labels-lineage 
representative strains. Numbers on branch length-bootstrap values (70-100). 
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Evolutionary analysis of Beijing sub-lineage 2.2.1.1 strains revealed that 49/83 (59%) belonged to 
clades previously identified in Daru Island, PNG (Figure S3-4) while the rest of the strains (41%) 
were in unique clades. Strains from Australian residents represented clade C, which we inferred to 
have its most recent common ancestor in the 1970s. 
 
3.4.3 Transmission 
On accessing the SNP distribution among strains from the same locality versus strains from different 
locality especially for villages with the highest representative numbers for the different lineages, a 
threshold of 8 SNPs was deduced to distinguish transmission links (Figure S3-6). The cut-off is 
similar to those used in other studies (124, 128). There were 17 genomic clusters (14-Beijing lineage, 
three-Euro-American lineage) constituting of 74 isolates (65-Beijing lineage, nine-Euro-American 
lineage) (Figure 3.4). Genomic clusters among the Beijing lineage strains were mostly from 
Mabadauan (89%, 34/38) while genomic clusters among the Euro-American lineage strains were 
mostly from Sigabadaru (100%, 4/4). There was statistical significance for genomic clusters formed 
among isolates of the same locality (41 Beijing isolates, 5 Euro-American) than across the different 
localities (P=0.0013). There was median 2 (IQR 1-3) SNP difference among genomic clusters from 
the same locality and 4 (IQR 2-6) SNPs among genomic clusters from different locality. Of the 
epidemiologically linked Australian cases, 3 (including the index case) formed part of an MDR-TB 
cross-border cluster at one SNP difference, while the fourth isolate was linked to another MDR-TB 
cluster at zero SNP difference suggesting two independent plausible episodes of cross-border 
transmission. 
 
3.4.4 Risk factors of transmission 
Table 3.1 details the characteristics of cross-border TB patients, according to the Mycobacterium 
tuberculosis strain lineage identified. Most cases (74/100) (74%) were young persons (<35 years of 
age), indicative of active transmission events, while both genders were evenly represented.  Only 1 
of 74 (1.3%) patients tested had human immunodeficiency virus (HIV) co-infection. There were no 
major differences in the characteristics of patients infected with Beijing or Euro-American lineage 
strains, except that drug resistance was strongly associated with Beijing sub-lineage strain (31/79, 
p<0.0001).  Table 3.2 reflects patient characteristics associated with transmission as demonstrated 
by genomic clusters of Beijing and Euro-American lineage strains. Univariate analysis revealed 
Beijing sub-lineage (OR 6.190 95% CI 2.221-18.077 p<0.0005) and resistance to first and second-
line TB drugs (OR 4.677 95% CI 1.452-20.943 p=0.019) were most strongly associated with 
transmission. In multivariate logistic analysis, we adjusted for only the two significant characteristics 
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from univariate analysis and showed Beijing sub-lineage to be associated with transmission (OR 
4.484 95% CI 1.526-13.891). The single HIV-infected patient identified was not part of a cluster. 
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Figure 3.5: Correlation of phenotypic and genotypic drug resistance among modern Beijing strains 
from the Torres Strait Protected Zone 
 
*Pairs of co-occurring mutations observed within the same strain; embA-embB (C-15T) and embB 
(p.Asp354Ala), embB (p.Gly406Val) and embB (p.Met306Ile). No resistance mutation (black bar-
kanamycin) 
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Figure 3.4: Genomic clusters among the Beijing sub-lineage and Euro-American lineage (inset) 
strains. Each circle represents a strain, with larger circles representing two or more patients with 
identical sequences. Patient details within each circle is the locality; M-Mabadauan, D-Daru, T-Ture 
Ture, S-Sigabadaru, OM-Old mawata, KAD-Kadawa, KUN-Kunini, KIW-Kiwia, KUR-Kurunti, DI-
Dimiri, UN-Unknown, BU-Buji, KAT-Katatai and QLD-Queensland; blue (blue outline)-susceptible, 
red (blue outline)-MDR, red (green outline)-XDR and purple (blue outline)-strains identified from 
Australian residents. Solid lines illustrate genomic plausible transmission links among strains from 
the same locality while broken lines represent plausible transmission links among strains from 
different localities. Number on the lines represents SNP differences between strains. 
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Table 3.1: Characteristics of TB patients identified in the Torres Strait Protected Zone, according to 
the strain lineage identified 
Characteristic  Category Total (%) 
Strain Lineage 
p-value* 
Beijing  
Euro-
American  
Age 
<15 19 (19.0) 15 4 
0.739 
15-24 31 (31.0) 26 5 
25-34 24 (24.0) 19 5 
35-49 18 (18.0) 13 5 
≥50 8 (8.0) 6 2 
Year  
2010 29 (29.0) 22 7 
0.324 
2011 42 (42.0) 33 9 
2012 13 (13.0) 12 1 
2013 2 (2.0) 1 1 
2014 8 (8.0) 5 3 
2015 6 (6.0) 6 0 
Sex 
Female 45 (45.0) 35 10 
0.876 
Male 55 (55.0) 44 11 
Sputum smear 
Negative 46 (46.0) 34 12 
0.599 
Positive 54 (54.0) 45 9 
HIV status 
Unknown 26 (26.0) 20 6 
0.234 Negative 73 (73.0) 59 14 
Positive 1 (1.0) 0 1 
Previous TB episode 
No 87 (87.0) 68 19 
0.653 
Yes 13 (13.0) 11 2 
Diagnostic delay (days) 
0-30 53 (53.0) 44 9 
0.484 31-60 18 (18.0) 14 4 
61> 29 (29.0) 21 8 
MDR/XDR 
No 69 (69.0) 48 21 
<0.001 
Yes 31 (31.0) 31 0 
Type of TB 
Pulmonary 53 (53.0) 43 10 
0.741 Extra pulmonary 7 (7.0) 5 2 
Both  40 (40.0) 31 9 
Started TB treatment 
No 22 (22.0) 15 7 
0.472 
Yes 78 (78.0) 64 14 
TB treatment outcome 
Transferred; lost to 
FU 66 (66.0) 52 14 
0.216 Cure or complete Tx  22(22.0) 15 7 
Defaulter 3 (3.0) 3 0 
Died 9 (9.0) 9 0 
 
*p-value calculated using the Fishers exact test; TB – tuberculosis; HIV– human immunodeficiency 
virus; M/XDR – Multi and Extensively drug resistant; FU - follow-up 
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Table 3.2: Patient characteristics associated with Mycobacterium tuberculosis strain clustering#. OR 
– Odds ratio; CI – Confidence interval; FU – follow-up; Tx – treatment; M/XDR – Multi- and 
Extensively drug resistant, NA – Not applicable (large value); #Irrespective of strain lineage 
*aOR–adjusted odds ratio for Beijing sub-lineage and M/XDR  
 
Characteristic 
Clustered/Total     
Adjusted odds 
(aOR)*   
74/100 OR (95%CI) p-value aOR (95% CI) p-value 
Beijing sub-lineage           
No 9/21 1   1   
Yes 65/79 6.19 (2.22-18.07) 0.0005 4.48 (1.53-13.89) 0.007 
Age           
<15 14/19 1   1   
15-24 25/31 1.49 (0.37-5.84) 0.57 1.29 (0.29-5.61) 0.725 
25-34 19/34 1.36 (0.32-5.78) 0.67 1.24 (0.26-5.98) 0.782 
35-49 12/18 0.71 (0.17-2.95) 0.64 0.72 (0.15-3.42) 0.679 
≥50 4/8 0.36 (0.06-2.02) 0.24 0.26 (0.04-1.79) 0.173 
Sex           
Female 34/45 1   1   
Male 40/55 0.86 (0.34-2.12) 0.748 0.86 (0.31-2.28) 0.757 
Sputum Smear           
Negative 32/46 1   1   
Positive 42/54 1.53 (0.62-3.81) 0.352 1.15 (0.42-3.09) 0.784 
Case type           
New case 63/87 1   1   
Recurrent (reTx) 11/13 2.09 (0.51-14.18) 0.358 1.45 (0.27-11.28) 0.684 
Diagnostic Delay           
0-30 40/53 1   1   
31-59 13/18 0.85 (0.26-3.03) 0.784 1.042 (0.29-4.15) 0.95 
≥60 21/29 0.85 (0.31-2.46) 0.761 1.157 (0.38-3.74) 0.799 
MDR/XDR           
No 46/69 1   1   
Yes 28/31 4.68 (1.45-20.94) 0.019 2.774 (1.53-13.89) 0.143 
Treatment 
outcome           
Cure; Tx completed  13/22 1   1   
Transferred; lost to 
FU 50/66 2.16 (0.77-6.01) 0.138 1.794 (0.58-5.41) 0.298 
Defaulted 2/3 NA NA NA NA 
Died 9/9 NA NA NA NA 
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3.4.5 Phenotypic and genotypic susceptibility 
Phenotypic DST of all strains showed that 53 (50.9%) strains were susceptible to all first-line drugs 
tested; 1 (1.8%) had streptomycin mono-resistance (Table S3-3). Drug resistance patterns observed 
included 13.5% (14/104) with isoniazid and streptomycin co-resistance, 31.7% (33/104) with MDR 
(1 pre-XDR with fluoroquinolone resistance) and 2 (1.9%) with XDR. All MDR and XDR strains 
belonged to previously described clades C and D from the Beijing sub-lineage 2.2.1.1, including 
strains from Australian residents tested. There was a good correlation between phenotypic and 
genotypic resistance profiles, except for ethambutol. Figure 3.5 shows drug resistance and 
compensatory mutations identified in all strains. Of the 35 strains that had second-line DST 
performed, all carried a fabG1-inhA mutation (C-15T). Of the 28/35 (80%) strains that had high level 
(0.4µg/ml) isoniazid resistance, 27/28(96.4%) had both ndh (Del G304) and inhA mutation 
(p.Ile21Val), while one had a katG mutation (p.Trp191Arg). All the rifampicin resistant strains had 
the same rpoB mutation (p.Ser450Leu) and 29 (29/35; 82.8%) had compensatory mutations in rpoC 
gene (27 with p.Val483Gly and 2 p.Trp484Gly). Notably, nearly all (96.5%; 28/29) strains with 
compensatory rpoC mutations and strains with fabG1-inhA mutation (97.9%; 48/49) were part of a 
genomic cluster. Of the two strains with p.Asp94Ala gyrA mutation typical of fluoroquinolone 
resistance; one was an XDR-TB with pan-second-line-injectable resistance (including amikacin, 
capreomycin and kanamycin) associated with an rrs mutation (A1401G). The second XDR 
(previously treated in PNG) had a p.Asp89Asn gyrA mutation and phenotypic resistance to 
kanamycin without a detected mutation conferring kanamycin resistance. Mutations in genes 
potentially conferring resistance to other agents including newly available agents were not identified. 
3.5 Discussion 
This is the first study to characterize Mycobacterium tuberculosis strain diversity, transmission 
dynamics and drug resistance profiles among cross border patients in the TSPZ.  This region is known 
for its unique geographical, ethnic and social diversity that may make disease surveillance difficult. 
Findings from this study underscore the risk of cross-border importation of tuberculosis including 
highly drug resistant strains with potential for epidemic spread. Studies from other parts of Australia 
suggest very limited local TB transmission despite a high proportion of imported TB cases (159, 212), 
but these findings mainly reflect the situation in affluent metropolitan areas. Residents of the Torres 
Strait and traditional visitors from PNG may be vulnerable to community outbreaks given close 
cultural and family relationships, factors which have been demonstrated in other community 
outbreaks within Australia amongst indigenous people (213). Unsurprisingly, most transmission in 
this region was shown to be caused by local community outbreaks as demonstrated by higher genomic 
clustering among patients from the same locality than from different localities (P=0.0013).  
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There was dominance of modern Beijing sub-lineage 2.2.1.1 strains circulating among the patients 
but the diversity of Euro-American sub-lineage strains is worth noting. We recently attributed strains 
from the same Beijing sub-lineage strain to be responsible for the a large MDR-TB outbreak on Daru 
Island, which is located along the PNG coast approximately 50 km east of the outer islands of the 
Australian Torres Strait (214). The MDR-TB outbreak on Daru Island has been highlighted as 
“unprecedented’ in scale (215) but no published information explores the extent of this outbreak 
beyond the shores of Daru Island. We identified Mabadauan village as another potential ‘hotspot’ for 
MDR transmission in Western Province, PNG. There is need for more knowledge as to whether the 
dominant Beijing strain is responsible for drug resistance in other settings in PNG. The expansion of 
the strain associated with MDR-TB underscores the urgent need for effective clinical and public 
health related interventions to control MDR-TB transmission. Wide spread dissemination of Beijing 
MDR-TB clades has previously been observed in Eastern Europe and attributed to the collapse of 
public health systems  in former Soviet Union states during the 1990s (142). The Beijing sub-lineage 
identified in this region has a long evolutionary history with introduction into the Western Province 
of PNG estimated to have occurred in the 1940s/50s and emergence of resistance to first line drugs 
estimated to have occurred in the 1980s (109). The observed genomic diversity within the sub-lineage 
provides evidence of ongoing microevolution, which could further influence transmissibility, 
acquisition of drug resistance or severity of disease (216).   
 
This study identified two plausible independent episodes of drug resistant TB transmission to 
Australian residents in the TSPZ which couldn’t be identified by conventional genotyping techniques. 
Other studies have showed the superiority of WGS over the conventional genotyping tool in resolving 
transmission in areas dominated by Beijing strains (154, 217). Two of the Australian MDR-TB 
patients in this small cluster were residing in major North Queensland urban centres at the time of 
their TB diagnosis, one in a residential congregate setting, which demonstrates the potential to 
disseminate in the community and nosocomial spread of the highly successful regional MDR-TB 
Beijing strain. WGS confirmed that the initial drug susceptible strain noted in the index MDR-TB 
case from the Australians in TSPZ was a lineage 4 strain with only streptomycin resistance (gidB, 
Leu79Ser). The strain was unrelated to other Euro-American strains identified in cross border patients 
and clearly different to the subsequent MDR Beijing strain isolated from the same patient, consistent 
with a new infection representative of exogenous reinfection or endogenous reactivation rather than 
recurrent infection with acquired resistance (218). 
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The first acquisition of MDR-TB by an Australian resident of the Torres Strait Islands through cross 
border transmission and secondary spread of an MDR strain under a well-functioning health system 
serves an important reminder of the dangers of drug-resistant tuberculosis. This result highlights one 
of the challenges faced by low burden countries in controlling transmission from neighboring high 
burdened countries due to international travels and migration. A recent European study utilized WGS 
to investigate multi-drug resistant TB outbreaks among immigrants and traced transmission routes to 
strains circulating in northern Somalia or Djibouti (219). Although there was no evidence of 
transmission to European nationals in that study, our current study proves the principle of MDR-TB 
cross-border transmission hence the need for increased regional TB surveillance between PNG and 
Australia. Although the number of TB cases among Australians in TSPZ was low during the study 
period, there were high numbers identified among cross-border patients prior to 2012 which can be 
attributed to the number of PNG residents managed in outreach clinics located on outer Torres Strait 
Islands, close to the PNG border. These clinics were closed in 2012 with formal handover of all PNG 
resident patients to the Western Province TB programme and enhanced TB services coordinated from 
Daru Island, accounting for a sharp fall in notifications (Fig S1).  
There was an observation of transmission by a locally evolved Beijing sub-lineage strain that was 
associated with resistance to first and second-line TB drugs. Beijing strains are known to be 
associated with increased transmissibility (220-222), drug resistance, treatment failure and rapid 
progression to active disease (125, 223). Similar to our previous findings among the Daru clades, the 
Beijing strain possessed a mutation in the regulatory protease gene mycP1 and was noted in TSPZ 
clades C and D at the earliest nodal point of recent evolution. Further study is required to assess 
whether this mutation may enhance virulence through dysregulation of ESAT6 and CFP10 secretion 
(193).  
Although WHO estimates a TB incidence amongst people living with HIV in PNG as high (44 per 
100,000 population) (1), HIV incidence in our described cohort is very low and does not account for 
the highly successful transmission of Beijing strain 2.2.1.1 in this region. A previous study reported 
only two HIV-infected cases among 105 TB cases identified in Gulf Province, which is adjacent to  
Western Province in PNG (163). The young age of adult TB cases suggests ongoing TB transmission, 
which is consistent with findings from a recent study that identified 76.6% of pediatric TB 
notifications in Queensland were PNG residents in the TSPZ (224). 
Excluding ethambutol, there was near perfect correlation between known resistance mutations 
identified and phenotypic in vitro resistance.  Surprisingly, one XDR-TB strain had in vitro resistance 
to kanamycin at 2.5µg/ml critical concentration and a microbroth dilution MIC of 10 µg/ml, but no 
known resistance conferring mutation was documented.  Kanamycin inhibits protein synthesis by 
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binding to the 16S rRNA in the 30S ribosomal subunit and resistance is observed at high level with 
rrs mutations (especially A1401G and G1484T) (225). Strains with low-level kanamycin resistance 
are generally thought to display resistance to kanamycin only among the aminoglycoside drugs, 
caused by eis promoter mutations (226, 227). Only 80% of phenotypic kanamycin resistance can be 
accounted for by known gene mutations, highlighting unexplained mechanisms of kanamycin 
resistance (227).  
Similar to chapter two (2.4.2), high level isoniazid resistance was associated with fabG1-inhA 
mutation and additional inhA (p.Ile21Val) mutation as previously reported in other studies (185, 186). 
The presence of fabG1-inhA (C-15T) mutation does seem to suggest successful spread and has 
previously been documented in clustered Mycobacterium tuberculosis strains in South Africa (221, 
228). One strain displayed a fabG1-inhA (C-15T) mutation together with katG gene mutation 
(p.Trp191Arg), which can affect the conformation of catalase peroxidase protein since it is found 
outside the active binding site of isoniazid (229). Another study of 202 isoniazid resistant isolates, 
identified only one isolate with katG gene mutation (p.Trp191Arg), which highlights it’s infrequent 
occurrence (23). The identification of different mutations associated with high-level isoniazid 
resistance highlights the ongoing selective pressure caused by isoniazid despite acquiring a fabG-
inhA (C-15T) mutation (230).  
Unexpectedly, most observed rifampicin-resistant isolates had mutations in rpoC gene. The fitness 
cost associated with some drug resistant mutations can be ameliorated by compensatory mutations 
that restore its ability to spread within a community (155). The vast majority of strains (96.5%) with 
rpoC compensatory mutations demonstrated genomic clustering, which signifies its likely role in 
MDR/XDR-TB transmission. An assessment of MDR strains in Argentina found no evidence to 
support the role of rpoC mutations in fitness restoration and increased transmission (162). Higher 
proportions of compensatory mutations in MDR outbreaks have been reported in areas such as 
Shanghai, China (66%) (125) and Samara, Russia (87%) (154).  
Several potential limitations of the study should be acknowledged.  The retrospective study design 
involved selection of only one isolate per patient over a 6-year time-frame and lack of detailed 
epidemiological information could have limited our understanding of risk factors involved in 
transmission. A significant number of stored isolates were unable to be studied due to failure of 
successful culture recovery. With the constructed genomic clusters, confirmation of close social 
contact among the linked patients couldn’t be done. Other epidemiological studies report refined 
breakdown of transmission patterns using a similar approach in the presence of close-contact 
information (124, 125, 219). It is important to appreciate that there is bidirectional movement of 
people within the TSPZ with opportunities for transmission by travel from or into PNG where the TB 
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incidence is substantially greater than in the Australian Torres Strait Islands. Although the current 
scope of the study comprised of mostly PNG residents, there is need for additional understanding of 
evolutionary and transmission dynamics among all residents in TSPZ, including drug susceptible 
strains in Australian TSPZ residents to assess the implications of transmission to populations on the 
mainland.  
Findings from this study confirm wide distribution of a Beijing sub-lineage strain associated with 
MDR/XDR TB in the TSPZ which threatens regional TB control through cross-border transmission.  
Further investigation of the environmental, socio-cultural and clinical factors that facilitate TB 
transmission in this region is warranted. There is need for increased strengthening of regional 
surveillance programs that should establish WGS to supplement the current measures for improved 
control strategies. 
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Chapter 4: Long-read sequencing of extensively drug resistant Mycobacterium tuberculosis 
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4.1 Abstract 
 
A better understanding of the genomic changes that facilitate the emergence and spread of drug 
resistant Mycobacterium tuberculosis strains are currently required.  Here, MinION nanopore 
sequencer (Oxford Nanopore Technologies) was used to sequence and assemble an extensively drug 
resistant (XDR) isolate, which is part of a modern Beijing sub-lineage strain, prevalent in Western 
Province, PNG.  Using 238 fold coverage obtained from a single flow-cell, de novo assembly of 
nanopore reads resulted into one contiguous assembly with 99.92% assembly accuracy. Incorporation 
of complementary short read sequences (Illumina) as part of consensus error correction resulted into 
4404064bp genome with 99.98% assembly accuracy. The assembly had average nucleotide identity 
of 99.7% relative to the reference genome, H37Rv. Majorly all GC rich-repetitive PE/PPE family 
genes (166/168) were assembled and identified variants within these genes. With an estimated 
genotypic error rate of 5.3% from MinION data, identification of mutations to include conventional 
drug resistance mutations, those that contribute to resistance phenotype (efflux pumps/transporter) 
and virulence was demonstrated. Reference based alignment of the assembly allowed detection of 
deletions and insertions. MinION sequencing provided a fully annotated assembly of a transmissible 
XDR strain from an endemic setting and showed its utility to provide further understanding of 
genomic processes within Mycobacterium tuberculosis.
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4.2 Introduction 
Globally, the tuberculosis (TB) incidence rate has shown a slow decline over the last two decades, 
although absolute case numbers continue to rise due to population growth, with an estimated 10.4 
million new cases occurring in 2016 (1). TB control gains are threatened by the growing number of 
drug resistant strains recorded around the world (150). An estimated 490,000 incident cases of MDR 
TB, which is resistance to at least isoniazid and rifampicin occurred in 2016 (1). The incidence of 
XDR strains, which are MDR strains with additional resistance to at least one fluoroquinolone and 
second line injectable, is also on the rise (1). Further multiplication of drug resistance in strains that 
are already highly drug resistant could lead to programmatically incurable TB, where construction of 
a curative regimen might be impossible with existing treatment options (74, 231). Management of 
drug resistant tuberculosis places a major financial burden on health systems, which may be 
overwhelming in settings with high disease burdens (74).  
 
In the absence of lateral gene transfer (152), drug resistance in Mycobacterium tuberculosis arises 
mainly from chromosomal mutations that are selected by chemotherapeutic pressure, which drives 
drug resistance multiplication and the ongoing evolution of drug resistant strains (162, 185, 232). 
Successful transmission of drug resistant strains results in clonal expansion and potential epidemic 
spread (154, 160, 161). The acquisition of resistance-conferring mutations has potential for epidemic 
spread if these drug resistant strains are readily transmissible (233, 234).  The mechanisms underlying 
the development of highly transmissible XDR strains are not fully elucidated. One such mechanism 
is the induction of efflux pumps, which may lead to high level resistance in mycobacteria (192), 
without any metabolic compromise. While previous studies described efflux pump coding genes and 
identified mutations in some of the genes to cause resistance (235, 236), this is yet to be described 
among a transmissible XDR strain.  
 
WGS using short-reads has elucidated a large number of mutations associated with drug resistance, 
as well as compensatory mutations, but has limited capacity to resolve large structural variations, 
gene duplications or variations in repetitive regions (154, 237, 238). Long-read sequencing could 
provide a more comprehensive understanding of the evolutionary mechanisms underlying the 
emergence of highly transmissible drug resistant strains (237). In principle, Oxford nanopore MinION 
sequencing technology offers read lengths that are only limited by the length of DNA presented and 
produces data in real-time (239). The small size, ease of use and cheap unit cost of the Oxford 
MinION® nanopore sequencer facilitates successful deployment in resource-limited settings, as has 
been achieved during the Ebola outbreak in West Africa (240). Although the potential of Oxford 
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MinION® to detect drug resistance mutations in Mycobacterium tuberculosis has been demonstrated, 
(133) its application for complete Mycobacterium tuberculosis genome assembly has not been 
reported. 
 
Papua New Guinea has a high rate of drug resistant TB in its Western Province (164). 
Characterization of a drug resistant strain in Daru was described in chapter two. Whilst some genetic 
markers within the strain have been identified (109), the molecular mechanisms responsible for 
pathogenesis and virulence are not fully elucidated. Genomic regions namely; proline-glutamate (PE, 
99 loci) and proline-proline-glutamate (PPE, 69) genes are thought to contribute to virulence and 
pathogenicity of a strain (146, 241) and yet they are routinely excluded from data analysis after WGS  
(109, 142, 161). These gene families constitute signature motifs near the N-terminus of their gene 
products and are sub classified according to sequence features on the C-terminus. PE genes are 
divided into PE_PGRS (polymorphic GC-rich sequence, 65 genes) and PE (no distinctive feature, 34 
genes) while PPE genes is divided into PPE_MPTR (major polymorphic tandem repeats, 23 genes), 
PPE_SVP (Gxx-SVPxxW motif, 24 genes), PPE_PPW (PxxPxxW motif, 10 genes) and PPE (no 
distinctive feature, 12 genes) (241). The existence of these subgroups highlights the diversity in their 
roles towards immune invasion and virulence (148). Functional studies have demonstrated that some 
PE/PPE proteins are frequently localized to the cell membrane and specifically inhibiting macrophage 
functions (241). For example PE_PGRS62 inhibits phagosome maturation (242), PE5 and PPE15 
inhibit reactive nitrogen species production (243), PE_PGRS30 inhibits phagolysosomal fusion 
(244). PGRS domains have been shown to inhibit antigen processing (245).  
 
Because of the repetitive nature of nucleotides and GC rich content (~80%) within the PE/PPE gene 
regions, they are a source of sequencing error from short read sequencing like Illumina. Previous 
studies have utilized Illumina sequencing to provide understanding of the role of these gene families 
but some of the reported results are variable and inconsistent with no complete assembly of these 
genes (148, 246, 247). A study by Elghraoui and colleagues utilized small molecule real time (SMRT) 
sequencing which produces long reads to assemble a complete genome of Mycobacterium 
tuberculosis H37Ra that included all the PE/PPE gene families (248). However, this was performed 
on an attenuated strain, there remains a need to use cheap long read sequencing technology on drug 
resistant strains to provide insight into the underlying mechanisms of drug resistance and identify key 
features associated with virulence and transmissibility. We utilized Oxford MinION® to assemble a 
comprehensive genome of an XDR strain including variable and repetitive regions such as PE/PPE 
genes. The assembly will serve as an ideal reference for ongoing MDR/XDR outbreak surveillance 
in Western province, PNG and far north Queensland. 
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4.3 Methods 
4.3.1 Phenotypic susceptibility testing 
Of the 6 XDR isolates originating from Western Province PNG that were previously characterized in 
section 2.4.3,  one of them was randomly selected and designated as WP-XDR strain for this study. 
It had first and second line drug susceptibility tested as previously described in section 2.3.2. 
4.3.2 DNA extraction and quantification   
DNA was extracted from Lowenstien-Jensen (LJ) slopes cultured for 4 weeks at 37oC. DNA isolation 
was performed using mechanical and chemical methods. Briefly, 5 glass beads (0.7mm, SIGMA) 
were added to 700µl of PrepMan Ultra sample preparation reagent (Thermo Fisher scientific, 
Massachusetts, USA). Full loops of culture were added to the reagent and mixed well. The solution 
was dry heat incubated for 10 minutes at 95oC, followed by bead beating for 40s at 6.0m/s using mini-
beadbeater-16 (BioSpec products, Bartlesville, USA). It was then centrifuged for 10 minutes at 
13,000rpm before transferring 450µl of the supernatant into another vial. 45µl of 3M sodium acetate 
and 1ml of ice-cold ethanol (96%) were added, centrifuged the solution at maximum speed for 15 
minutes and removed the supernatant. We then added 1 ml of 70% ethanol, left it at room temperature 
for 1 minute, and again removed all the supernatant. The remaining pellet was dried for 15 minutes 
and re-suspended with 40µl of nuclease free water. The DNA was quantified using Nanodrop 8000 
(Thermo fisher scientific, Massachusetts, USA) and Qubit dsDNA HS assay kit (Thermo fisher 
scientific, Massachusetts, USA). 
 
4.3.3 MinION® library preparation and sequencing 
DNA was purified using 0.4X Agencourt® AMPure® XP beads (Beckman Coulter) and fragment 
distribution size assessed using Agilent 4200TapeStation (Agilent, UK). Preparation for 1D gDNA 
library was performed using the SQK-LSK108 manufactures’ instructions.  We performed dA-tailing 
and end-repair using NEBNext Ultra II End-repair/dA-tail module with two step incubation times; 20 
minutes each. Then, purification step using 0.7X Agencourt® AMPure® XP beads (Beckman 
Coulter) was performed according to manufacturers’ instructions. Ligation step was performed using 
NEB Blunt/ligase master mix module according to manufacturers’ instructions and reaction incubated 
at room temperature for 20 minutes. Adaptor-ligated DNA was purified using 0.4X Agencourt® 
AMPure® XP beads (Beckman Coulter) following manufacturers’ instructions but using Oxford 
Nanopore supplied buffers (adaptor bead binding and elution buffers). The library was ready for 
MinION® sequencing. 
With the MinION MK1B device connected to the computer via a USB3, MinKNOW software 
(v.1.4.3) was started to perform quality control checks on pore activity and equilibrate the flow cell 
(FLO-MIN106, version R9.4). The library was combined with reagents supplied by Oxford Nanopore 
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and loaded onto the flow cell following manufacturers’ instructions, choosing a 48h sequencing 
procedure. Illumina data for the isolate was available from chapter 2 study. Illumina and MinION 
sequencing reads generated and analysed are available in NCBI under project accession number 
PRJNA386696.  
4.3.4 MinION® and Illumina data analysis 
Raw files generated by MinKNOW were base called using Albacore (v2.0) to return Oxford 
Nanopore Technologies (ONT) fastq files. De-novo genome assembly was performed using Canu 
v1.5 (249) and the assembly was improved using nanopolish v0.9.0 (metlylation aware option) (250). 
Then, sequence depth of coverage of ONT reads was assessed using SAMtools v0.1.19-1 (251). The 
assembly was further improved through two different error correction steps; Racon v1.0.0 (utilizing 
raw ONT reads), Pilon v1.21 (utilizing Illumina reads) (252) and combination of both Racon and 
Pilon . CheckM v1.0.11 was utilized to assess the quality (completeness and heterogeneity) of the 
assemblies (253). To determine the accuracy of the assemblies, Illumina reads of the study strain were 
first de-novo assembled using SPAdes v3.11.1 (254). The resultant Illumina assembly was used to 
determine the accuracy of ONT assemblies by using statistics from dnadiff (MUMmer version 3) 
(255). The assembly with the best qualities was circularized using Circulator v1.5.1 (256), similarity 
with the reference genome H37Rv (NC_000962.3) was determined using nucmer (MUMmer version 
3) (255) and Average Nucleotide Identity (ANI) calculator (257). Genome annotation was performed 
using the NCBI pipeline (258) and circular representation of the genome viewed using Circos v.67-7 
(259). To evaluate the assembly of PE/PPE gene families, all the PE/PPE gene sequences within 
Mycobacterium tuberculosis H37Rv were searched from Mycobrowser (260) and used to create a 
customized PE/PPE database. Blastn of the assembly against the database was performed. Percentage 
breadth of coverage and read depth for PE/PPE gene families from ONT and Illumina reads was 
assessed using DepthOfCoverage (GATK v3.4 version 3.7) (173) after mapping to H37Rv using 
BWA-MEM v0.75 (172). The resultant depth were plotted using ggplot (R statistical package). 
Biodiff (https://www.gitlab.com/LPCDRP/biodiff) was used to call structural variants from the 
assembly against H37Rv as a reference and as a query. Structural variants were further evaluated by 
mapping Illumina raw data of lineage representative genomes including Indo-Oceanic, East-Asian 
(including Beijing lineage), East-African-Indian and Euro-American lineage and H37Rv from 
previous studies (109, 128, 142, 261), to the assembly and H37Rv reference genome, then used 
Sniffles (262) on the resultant files. The identified insertion sequences within the assembly had GC 
content calculated using GC calculator (Biologics International Corp, Indianapolis, USA). Blastn and 
Phyre2 (263) were used to query and  predict protein structure of structural variants identified within 
the assembly. 
 
69 
 
4.3.5 Genotyping comparison between MinION and Illumina data 
Using the reference genome H37Rv, single nucleotide polymorphisms (SNPs) and small indels 
(<5bp) were called from ONT reads using nanopolish (250) and annotated using SnpEff (174). SNPs 
within PE/PPE were characterized. Polymorphisms in known drug resistance genes (including 
compensatory mutations) were analyzed. MycoBrowser (260) was utilized to annotate genes that are 
putatively involved in virulence, efflux pumps and cell transport and mutations within those genes 
were characterized. SNPs from Illumina reads were identified using a GATK workflow (Figure S4-
1) (173), consensus SNPs between Illumina and ONT was evaluated. Non-consensus SNPs from ONT 
reads were considered sequencing errors provided Illumina coverage was greater than 30X. This 
analysis excluded SNPs in PE/PPE genes (Table S4-1).  
4.4 Results 
4.4.1 Analysis of MinION derived assembly of WP-XDR strain 
In total, 373952 ONT reads passed base calling with N50 read length of 5073bp, longest read-
330509bp and average sequence depth of 238X (Figure 4.1). The size of the assembly varied among 
the different consensus tools used; Racon-4404947bp, Pilon- 4405333bp and Pilon plus Racon- 
4404064bp. Use of raw ONT reads for error correction of the assembly resulted into a 99.92% 
accurate assembly (Racon), while use of Illumina reads improved it further to 99.97% (PILON). 
According to CheckM results, the assembly from a combination of Pilon plus Racon tools had better 
quality scores and this was referred to as WP-XDR assembly. (Table 4.1). The single contig of 
4404064bp had GC content of 65.5% and with a 99.7% ANI score to H37Rv (Figure S4-2). NCBI 
annotation of the genome yielded a total of 3,697 coding DNA sequences (CDS), 45 tRNAs, 3 rRNAs 
(5S, 16S, 23S) and 3 non-coding RNA (Figure 4.2) (assembly and annotations are available in NCBI 
under accession number CP022704.2). Blastn analysis of PE/PPE customized database against the 
assembly genome showed 166/168 PE/PPE genes had >90% nucleotide sequence similarity at E-
score ≤ 10-6 (Figure S3). Two genes, wag22 and PE_PGRS57 had nucleotide sequence similarity of 
58.8% and 78% respectively. Evaluation of PE/PPE genes when ONT reads when mapped to H37Rv 
revealed nearly all PE/PPE genes (166/168) had 100% breadth of coverage at an average read depth 
of 299.87 (IQR 285.91-311.36) (Figure S4-3). Again wag22 and PE_PGRS57 had breadth of 
coverage of 26% and 62% respectively. From Illumina reads of the study strain, only 54.3% (92/168) 
of the PE/PPE genes had 100% breadth of coverage at an average sequence depth of 46.3 (Figure 
S4-4) with wag22 and PE_PGRS57 having zero coverage. 
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Table 4.1: CheckM quality evaluation and assembly accuracy of draft genomes obtained from 
the three consensus tools, relative to the spades assembly. Racon tool used ONT reads only, 
Pilon-Illumina reads only and Pilon + Racon-combination of ONT and Illumina reads 
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Figure 4 1: A bar graph showing sequence length distribution from ONT 
 
 
 
4.4.2 Genotypic error analysis MinION reads 
Evaluation of SNP calls in the non-repetitive part of the reference genome was first assessed by 
excluding repetitive PE/PPE regions.  A total of 1254 SNPs and 122 small indels were called from 
ONT reads while 1098 SNPs and 105 small indels were called from Illumina reads when mapped to 
H37Rv. Of these, 1095 SNPs (574 non-synonymous and 402 synonymous) and 87 small indels were 
identified by both approaches. 118 of 159 SNPs and 23 of 35 small indels identified from ONT but 
not in Illumina reads were from regions of low Illumina coverage (<30x coverage). The remaining 
41 SNPs (3.2%, 41/1254) and 12 small indels (9.8%, 12/122) identified in ONT but missing from 
Illumina (high coverage regions). These might potentially be due to systematic base-calling which 
could not be corrected via consensus calling and polishing. Three (0.2%) SNPs and 18 (14.7%) indels 
were identified by Illumina, but not by MinION® sequencing. Considering all 194 ONT only calls 
(159 SNPs and 35 indels) as false positives and 21 Illumina only calls (3 SNPs and 18 indels) as false 
negative, the genotypic error rate from all ONT calls was estimated at 15.6% (215/(1254+122)*100). 
If we ignore inconsistent calls where Illumina coverage was low then the estimated genotypic error 
rate for base calling from ONT was reduced to 5.3% (74/(1254+122)*100). Counts of SNP calling 
among the non-consensus SNPs from ONT reads did not show any bias to a particular base (Table 
S4-2).   
ONT and Illumina reads were assessed for SNPs identification in PE/PPE gene families. From ONT 
reads, 158 SNPs were identified from 70 PE/PPE genes (42 PE and 28 PPE) with 88 SNPs (55.6%) 
identified from the PE_PGRS sub-family (Table S4-3).  From the Illumina reads, 124 SNPs from 45 
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PE/PPE genes (25 PE and 20 PPE) were identified of which 31 SNPs (25%) were from PE_PGRS 
sub-family. There were 81 SNPs (from 42 PE/PPE genes) overlapping between ONT and Illumina 
with PPE54 having the highest number of overlapped SNPs (9) identified within one gene. 
 
Figure 4.2: Circular representation of the drafted WP-XDR genome with gene annotations. From the 
inner to outer ring: Blue - GC content of coding sequence; Scattered grey - SNPs relative to H37Rv; 
Grey bars - reverse and forward rRNA; Green - reverse coding sequences; Red - forward coding 
sequences; Yellow bars - unique regions compared to H37Rv; Grey outside ring - assembled contig 
(grey). Mb-million base pairs 
 
 
 
4.4.3 Mutations in known resistance genes, efflux pumps and virulent genes 
Phenotypic drug susceptibility results revealed the WP-XDR strain to be extensively drug resistant 
with susceptibility to only amikacin, kanamycin, para-aminosalicyclic acid (PAS) and cycloserine.  
Table 4.2 reflects phenotypic resistance, as well as mutations in genes known to confer drug 
resistance to first and second line drugs and recognized compensatory mutations.  Genotypic drug 
resistance profiles concurred with phenotypic results. While 10 mutations were identified in seven 
genes that encode trans-membrane efflux pumps and transporter proteins (Table 4.3). Table S4-4 
shows 16 SNPs identified in genes that encode virulence proteins; 8 (50%) were from the mce-gene 
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family and a mutation within mycP1 (p.Thr238Ala) was also noted. In addition, 27 SNPs were 
identified in three genes families involved in cell wall synthesis, with 17 in fadD, 4 in pks and 3 in 
mmp gene families (Table S4-5).  
Table 4.2: Mutations in candidate drug resistance genes identified from ONT assembly of XDR 
Beijing sub-lineage 2.2.1.1 strain.  
 
Drug 
Invitro 
phenotype 
Investigated genes Genes (mutation) 
Isoniazid Resistant 
fabG1-inhA, inhA, 
katG, ndh, furA, oxyR, 
aphC, fadE24, srmR, 
kasA, mshA  
fabG1-inhA (C-
15T) 
inhA (p.Ile21Val) 
ndh (delG304) 
Rifampicin Resistant 
rpoB, rpoC, rpoA, 
rpoD 
rpoB (p.Ser450Leu) 
rpoC 
(p.Val483Gly) 
Ethambutol Resistant 
embB, embC, embA, 
ubiA, embR, iniA, 
iniC, manB 
embB 
(p.Met306Val) 
Pyrazinamide Resistant pncA, rpsA, panD pncA(p.Tyr103Asp) 
Streptomycin Resistant rpsL, gidB, rrs 
rpsL (p.Lys43Arg) 
gidB (p.Leu91Pro) 
Ethionamide 
Resistant 
fabG1-inhA, ethA, 
ethR 
fabG1-inhA(C-15T) 
Fluoroquinolone Resistant gyrA, gyrB gyrA (p.Asp94Gly) 
Amikacin Susceptible rrs, whib7, gidB nil 
Kanamycin Susceptible 
Rv2417c-eis, whiB7, 
rrs, gidB 
nil 
Capreomycin Resistant tlyA, whiB7, rrs, gidB tlyA (ins397C) 
PAS Susceptible ribD, thyA, dfrA, folC nil 
Cycloserine  Susceptible alr, ddl, cycA nil 
 
ONT – Oxford nanopore technologies; XDR – Extensively drug resistant; PZA – Pyrazinamide; PAS 
- Para-amino salicylic acid 
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Table 4.3: Mutations in putative efflux pump/transporter genes identified from ONT assembly of 
XDR Beijing sub-lineage 2.2.1.1 strain 
 
Genes investigated Gene (mutation) identified 
drrA, drrB, drrC, Rv0194, pstP, 
efpA, bacA, mmr, Rv1250, 
Rv1272c, Rv1273c, Rv1634,  
Rv1258c, mmpL13a, mmpL13b, 
P55, jefA, Rv0849, Rv2456c, 
Rv3239c, Rv2994, secA1, pstB, 
Rv2265, Rv1217, Rv1218c, 
uspA, Rv2688c, Rv1819, 
Rv1877, Rv1273c, Rv1458 
Rv0194 p.Met74Thr 
Rv0194 p.Pro1098Leu 
secA1 p.Asp699Glu 
uspA p.Thr54Ser 
uspA p.Asp67His 
uspA Val127Leu 
glnQ p.Met243Leu 
Rv1218c p.Gln243Arg 
Rv1250 p.Arg278Gly 
Rv2688c p.Pro156Thr 
 
4.4.4 Structural variants identified from the WP-XDR assembly 
Two reference based approaches were utilized using biodiff script. First, using H37Rv as a reference 
to the assembly, known regions of difference for Beijing sub-lineage (264) and three unknown 
deletions (Table 4.4) were identified. On evaluating the three unknown deletions using Illumina data 
of lineage representative genomes that included H37Rv reads mapped to the reference, Sniffles 
identified the three unknown deletions still missing among the Beijing lineage representative 
genomes. Mycobrowser (260) annotation of genes spanning the unknown deletions identified these 
regions to be coding for probable transposase proteins. Secondly, using the assembly as a reference 
to H37Rv, two insertions within the WP-XDR assembly of size, 4490bp (2207139-2211629) and 
390bp (3488211-3488601) were identified. On assessing Illumina data of lineage representative 
genomes mapped on the WP-XDR assembly using Sniffles, the 4490bp insertion with 64.6% GC 
content was identified among indo-oceanic, ancient Beijing, modern Beijing, and east African Indian 
lineages but absent in Euro-American lineage (Figure 4.3). Like in previous studies (265-267), blastn 
and annotation results of the 4490 region was revealed to span 7 complete genes that encode proteins 
that include nicotinamide adenine dinucleotide phosphate (NADP)-dependent oxidoreductase, iron-
regulated elongation factor (Tu), PE-family protein and four genes that encode uncharacterized 
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proteins. The second smaller insertion, 390bp with 66.7% GC content (3488211-3488601) was 
identified as being unique to Beijing lineage genomes but varied in size as it was 835bp with respect 
to Indo-oceanic and East-African-Indian lineages (Figure 4.3). Review of NCBI annotation of the 
assembly indicated the insertion to be part of 654bp gene (CBG40_17120; 3487881-3488534) that 
span 323bp (3488211-3488534). A blast search of the insertion sequence revealed 50% sequence 
identity to four Mycobacterium tuberculosis H37Rv genomes (E-score=1.1E-175) and 100% 
sequence identity to 55 Mycobacterium tuberculosis, Lineage 2 genomes (E-score=0) (Table S4-6). 
Phyre2 protein modelling (263) of the 390bp insertion sequence was predicted to be a PPE-like 
protein with PE8-PPE15 protein was used as the best template (79% sequence modelled, 100% 
confidence) consisting of 73% alpha helices (Figure S4-5).  
Table 4.4: Characteristics of identified regions deleted from the WP-XDR genome relative to 
reference genome H37Rv. *Unknown deletions in the study strain 
 
Start Stop 
Size 
(bp) 
Region of 
Difference 
Genes deleted RNA deleted 
79557 83036 3,479 105 Rv0071, Rv0072, Rv0073 
ncRv10071, 
ncRv10071c 
1779278 1788514 9236 149 
Rv1573, Rv1574, Rv1575, 
Rv1576c, Rv1577c, Rv1578c, 
Rv1579c, Rv1580c, Rv1581c, 
Rv1582c, Rv1583c, Rv1584c, 
Rv1585c, Rv1586c 
nil 
1986636 1998623 11987 152 
plcD, Rv1756c, Rv1757c, cut1, 
Rv1759c, Rv1760, Rv1761c, 
Rv1762c, Rv1763, Rv1764, 
Rv1765c 
nil 
2365414 2366769 1355 * Rv2105, Rv2106 nil 
2535431 2536142 711 181 Rv2262c, Rv2263 nil 
3122553 3127944 5391 207 
Rv2816c, Rv2817c, Rv2818c, 
Rv2819c, Rv2820c 
nil 
3551229 3552585 1356 * Rv3184, Rv3185 nil 
3552710 3554025 1315 * Rv3186, Rv3187 nil 
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Figure 4.3: Integrative Genomic Viewer (IGV) of Illumina reads from different Mycobacterium 
tuberculosis lineages (A- Mycobacterium tuberculosis H37Rv, B-Indo-oceanic, C-Ancient Beijing, 
D-Modern Beijing, E-East African Indian, F&G-Euro American) mapped on the WP-XDR assembly 
highlighting the large insertions within the draft genome.  On the left-4490bp insertion (2207042-
2211532) spanning 7 annotated genes (blue checked arrows-NADH-dependent oxidoreducatse, Iron-
regulated elongation factor-tu, PE family protein and hypothetical/uncharacterized proteins). On the 
right-390bp insertion relative to H37Rv (3488211-3488601) spanning 323bp (checked) at the end of 
a 654bp coding sequence 
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4.5 Discussion  
Long read sequencing increases the potential for improved understanding of genomic factors that 
contribute to Mycobacterium tuberculosis phenotype since it has inherent power to assemble the 
entire strain genome. In this study, ONT was utilized to de novo assemble a genome for an XDR 
isolate that is part of modern Beijing sub-lineage strain, responsible for drug resistant TB outbreaks 
in the Western Province, Papua New Guinea (109). Just like other previous bacterial studies that have 
reported improved hybrid assembly of MinION and Illumina sequences (238, 268), the WP-XDR 
assembly was superior to MinION or Illumina only assembly. Other long read sequencing 
technologies like SMRT have also demonstrated their value in producing single contig assemblies of 
Mycobacterium tuberculosis genomes (248, 269) but such sequencing platforms are expensive and 
not field-friendly when compared to ONT. ONT has shown its utility in high-incidence settings for 
example in the Ebola virus epidemic of West Africa (270); which is suggestive of its future value in 
TB burdened settings especially in ‘hot spot’ drug resistance regions of PNG.  
 
Results from this study highlighted some of the advantages of using ONT. GC rich and highly 
repetitive PE/PPE gene families which were poorly resolved with Illumina reads were resolved with 
ONT reads. Of the two PE_PGRS sub family genes (PE_PGRS57 and wag22) that had poor assembly, 
wag22 has previously been shown to be deleted from Beijing lineage strains (264). There were twice 
as many SNPs in PE_PGRS genes by ONT over Illumina sequencing (Table S2). PE_PGRS gene 
mutations were under-represented in short-read sequencing, possibly due to their extra GC rich 
containing motifs that could impact on the sequencing. Previous studies have identified a higher 
number of mutations within the PE_PGRS sub-family compared to other PE subfamilies, and attribute 
it to their involvement in antigenic variation and immune evasion from exposure to host immune 
system (148, 271).  PPE54 which is a member of a larger sub-family, PPE_MPTR (major 
polymorphic tandem repeat) known to have more amino-acid variations at the C-terminal (147) had 
the highest number of mutations from ONT sequence. Previous studies have shown it to be involved 
in the ‘arrest’ of phagosome maturation to allow survival of the bacteria in the macrophages due to 
its long amino acid length at the C-terminal (146, 272).  It has been postulated that PPE54 gene 
mutations may also play a role in development of isoniazid, rifampicin and ethambutol resistance 
(273), but this couldn’t be verified since there was no negative control.  
 
Another advantage of ONT was the resolution of structural variants which are essential in 
understanding strain-related phenotypes (26). The identification of the three deleted gene coding 
regions that are almost the same size (1355bp, 1356 and 1315bp) is speculated to be evolutionary 
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mediated by insertion sequences within the genome. Moreover, the genes from the deleted regions were 
all coding for probable transposase proteins yet transposase proteins are known to be in cis proximity to 
insertion sequence (274). Presence of 4490bp insertion within the assembly and other lineages but 
absent in H37Rv shows its limitation when used as a reference genome in genomic studies. This could 
impact on the clear understanding of pathogenicity, virulence and transmissibility (265-267). The 
WP-XDR assembly has potential to be utilized as a reference genome for future XDR outbreak 
investigation in PNG. The second smaller insertion (390bp) within the assembly had variable sizes 
among the reference genomes which highlights evidence of independent structural rearrangement 
among the different lineages. The applied comparative approach highlights the opportunity to study 
lineage and strain specific differences, especially in the advent of long read sequencing which can 
provide complete assemblies.  
 
Although ONT had more differing variants when compared to Illumina, it had a good estimated 
genotypic error rate of 5.3%, identifying all the known drug resistance and compensatory mutations 
in concordance with in-vitro susceptibility testing. This was accompanied by characterization of 
mutations within efflux pumps/transporter, biosynthesis pathway encoding genes (ABC, MFS, 
mmpL, pks and fadD) and virulent genes (mce genes, mycp1)  which are thought contribute to the 
resistance phenotype and pathogenesis of the strain (275, 276). ONT data can confidently be utilized 
for further investigation of genomic variants that influence virulence, resistance and pathogenesis. 
Accompanied by the portability of ONT devices, this technology has potential for clinical utility as a 
point-of-care diagnostic tool since it generates reads that can be analysed in real time. This aspect 
was not explored in the current study but other studies have demonstrated the duration needed for 
speciation and identification of resistance conferring genes (240, 277). This is an on-going area of 
research whose future application in the diagnostics of MTB will greatly impact on improved 
management and control of infection. 
 
Some of the limitations of the study included the use of one isolate to identify various structural 
variants and mutations which could be ‘background’ variations that may not impact on the strain 
phenotype. Despite this, the known resistance conferring mutations were in concordance with the 
phenotype. Use of a polished consensus assembly for analysis of structural variants could have 
affected detection of assembly breaks although polishing step improved the quality of the assembly. 
Another limitation was the failure to confirm the presence of the identified structural variants using 
targeted sequencing although the variants were consistent with Illumina data that had high quality 
Phred score (>90). The non-consensus SNPs utilized for calculation of genotyping error for ONT 
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may not necessarily mean they are errors since non-consensual breaks (mis-assemblies) can occur 
within the assembly.  
 
In conclusion, this study shows the value of a portable small sequencer that can sequence XDR TB 
strains, assemble a complete genome including GC rich-repetitive regions and analyse variants with 
high certainty. Future application of this technology in high burdened settings will have absolute 
impact on TB control and case management.  
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5.0 Chapter 5: Conclusion and future directions 
5.1 Restatement of research aims  
There is an on-going spread of tuberculosis among people living in far north Queensland and Western 
Province, Papua New Guinea. The aim of this thesis was to use WGS to understand the evolutionary 
dynamics and transmission of the various strains circulating in these areas. Primarily, the intention 
was to investigate the bacterial genetics responsible for drug resistance and its evolution within 
Western Province of PNG. However, due to high incidence of tuberculosis in the Western Province 
and the existence of an open border policy between Queensland (Australia) and Western Province 
posing an imminent threat of cross border transmission between the two areas, the study included 
strains in far north Queensland. This led to utilisation of genomic and epidemiological data among 
PNG patients within the TSPZ to identify risk factors influencing the spread of tuberculosis. This 
study was utilised as a proof of principle for possible evidence of cross border drug resistance 
transmission to Australian population within the Torres Strait through the TSPZ. The last aim of this 
thesis was to investigate the utility of Oxford nanopore sequencing technology since it provides long 
read sequences that could be utilized to not only assemble the entire genome of an XDR but to provide 
proof for better understanding of variants within GC rich and repetitive regions like PE/PPE gene 
families. A handful of studies have utilized long read sequencing technology to provide insightful 
understanding of PE/PPE gene families despite the overall global interest of projects performing 
WGS in MTB.  
 
5.2 Key findings 
From chapter 2 and 3, dominance of a modern Beijing sub-lineage strain (2.2.1.1) was evident and 
its circulation within the population was estimated to have started in the 1940s. Beijing sub-lineage 
is the most ubiquitous lineage, found on all continents but its variants show differing pathogenic 
properties especially in areas with a high burden drug resistant TB (142, 216).  It is thought to have 
intrinsic biological properties that favour its rapid transmission, severe virulence, poor host response, 
treatment failures and acquisition of resistance (21, 140, 142). The observed Beijing sub-lineage 
strain has some features reminiscent to another Beijing variant that is considered to be the most 
successful MTB clone to have spread in the former Soviet Union and its immigrant communities 
(154, 278). Just like in the Samara study were they identified two major outbreak clades (154), the 
major outbreaks in Daru were identified to be responsible for evolution and transmission of drug resistant 
tuberculosis. It’s not surprising that these clades were identified among patients from the different 
TSPZ villages since the clades displayed capacity to spread without compromising fitness by 
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acquisition of compensatory mutations. It remains to be understood on a larger scale how 
geographically diverse this Beijing strain has spread within parts of PNG and Australia.  
 
One of the findings from chapter three showed two plausible independent routes of MDR 
transmission by the Beijing strain from PNG patients in the TSPZ to Australia residents in the Torres 
Strait. The fact that a maximum of one SNP separated any of the two outbreaks suggests a recent 
ancestor or direct transmission between patients. By contrast, MIRU-VNTR data could not 
distinguish between the outbreaks which illustrate its limitations in investigating transmissions in 
migratory populations. Supporting this was a recent study that investigated MDR TB outbreak among 
African refugees which found MIRU-VNTR to be poor at tracking the outbreak when compared to 
WGS (219). To optimise more gains of WGS in relation to effective public health response, there is 
not only the need to integrate this technology in outbreak response efforts but there is also need for 
more collaboration among all the stake holders governing public health in this region. This is 
important for improved regional monitoring of outbreaks and disease spread as it was demonstrated 
in the thesis that majority of the transmissions among the cross border patients were acquired locally.  
 
The rise in drug resistance to Mycobacterium tuberculosis is primarily through chromosomal 
mutations, (80) which implies that targeted sequence based tests are easy to set up and interpret. This 
has led to the successful implementation of nucleic amplification techniques like Gene Xpert 
MTB/RIF ultra as rapid diagnostic assays (64). Although targeted sequence assays target key 
resistance determining mutations, they may still result in doubt as to what other appropriate drug 
could be utilized for treatment (129). On the other hand, WGS can be offered as ‘one test’ to virtually 
characterise all the resistance markers (known and unknown) to explain phenotypic characteristics 
and detect transmission patterns. This phenomenon was evident in this thesis where good correlation 
between genotypic and phenotypic susceptibility was observed though there was imperfect prediction 
of ethambutol resistance phenotype. Previous WGS studies have identified the same inconsistency 
with this drug which illustrates the reproducibility and robustness of WGS hence warrant recalibration 
and reassessment of phenotypic assays for particular strain types (129, 131, 180).   
In some instances, WGS has been utilized to identify mutations responsible for resistance to novel 
drugs based on the knowledge base of the mechanisms of action resulting into appropriate design of 
new treatment regimens (84, 279). In this research, some putative novel markers responsible for 
resistance like mutations in srmR (isoniazid resistance), deletion of genes spanning pncA, ndh 
(pyrazinamide resistance, all in chapter two) were identified. This was accompanied by observation 
of other interesting mutations like double mutations in drug target genes, and mutations with 
susceptible phenotype (chapter two). Some of these occurrences illustrate how knowledge about MTB 
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resistance needs more description (280). Such mutations would need to be validated by approaches 
like in-vitro site mutagenesis or crystallographic protein analysis to ascertain their phenotypic effects 
(129). As more novel mutations are being identified, there is a need to assess their phenotypic 
characteristics and compilation of findings in curated multi-national databases (281) to act as 
reference points. Currently, at least two multi-national projects CRyPTIC (282) and ReSeqTB (283) 
are involved in collecting WGS data and corresponding phenotypic DST data. Databases like these 
will enhance our understanding of genotypic-phenotypic concordance.   
 
As more advances are being made in sequencing technologies, there is need to determine whether 
such technology can improve our understanding of the complexity of different genomic processes 
such as bacterial pathogenesis, virulence, drug resistance and host response. This would assist in 
providing better understanding for development of rapid diagnostic tests, vaccines or new drugs and 
hence improving the management of the tuberculosis disease. One such technology, GeneXpert 
MTB/RIF diagnostic assay has set precedence for deployment of advanced technology in low-income 
and high burdened settings (64). Oxford nanopore technology is also on the horizon to be utilized as 
a cheap, field friendly and cost effective whole genome sequencer with potential for future roll out in 
high burden settings (133). In this thesis, use of Oxford nanopore technology demonstrated its 
purpose in interrogating an XDR TB strain resulting into a complete genome assembly and accurate 
prediction of genotypic drug resistance mutations. Application of WGS to predict drug resistance will 
have high impact on future deployment of such technology in high-burdened settings such as Western 
province, PNG and assist in tracking of XDR outbreaks especially after assembling a reference 
genome. Use of local reference genome for genomic analysis allows identification of ongoing micro-
evolutionary processes and establishment of a full repertoire of genes among strains (266, 284).  
According to the current literature, there is no study that has utilized ONT in high burdened TB 
settings, although one study demonstrated its utility as a rapid and cheap technology in comparison 
to Illumina sequencing (133).  
There is growing need to fully characterize repetitive and GC rich regions like PE/PPE and determine 
their possible role in virulence and immune evasion. Currently, some PE/PPE antigens have been 
proposed as composite candidates for vaccines due to their cross-reactivity with other regions in the 
MTB genome though detailed understanding of specific function or immune response is lacking 
(285). M72 vaccine containing PPE 18 (GSK) and ID93 containing PPE 42 are both good examples 
of future prospects of utilizing these gene families for TB vaccine development (286). In this thesis, 
long reads were utilized to assemble virtually all PE/PPE gene families. This approach provides an 
opportunity to fully understand their diversity and function. Although there are previous studies that 
have utilized short read sequencing to try and understand these gene families, a cohesive 
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understanding of these genes using long reads is evident and this will result in prioritising candidates 
for functional studies hence new vaccines, drug targets or diagnostic markers. 
 
5.3 Future directions 
With the current advances in sequencing technology accompanied by the expanding collections of 
Mycobacterium tuberculosis, there is growing interest in carrying out more microbial genomics 
studies to hasten the understanding of TB genetics. Future work will build upon some of the findings 
in this thesis and hopefully refine the following aspects for further investigation hence improve 
patient care and management.  
 
The observed population structure showed dominance of Beijing sub-lineage strain circulating clades 
responsible for the on-going drug resistance in the studied area. Many of the studied principles that 
describe transmission and evolution can be applied to other settings. There is a need to determine the 
further spread of the Beijing strain to other regional areas since some of its clades are known for 
spreading drug resistance. This will provide further understanding of the clonal expansion and 
insights into the genetic basis for the success by the Beijing sub-lineage strain. Currently, there are 
interests in utilizing WGS and epidemiological information of TB strains (based on some of the 
findings from this thesis) circulating in Port Moresby, PNG since it’s another area at risk of drug 
resistance outbreaks (2018 NHMRC grant submitted). Since there was evidence of MDR transmission 
to Australians in the Torres Strait caused by the same Beijing sub-lineage strain, there is need to 
assess its further spread on the Australia mainland territory especially in north Queensland and areas 
of Eastern Indonesia. Future molecular epidemiology studies performed in these areas should utilise 
WGS and detailed epidemiological data to delineate transmission routes and socio-economic risk 
factors the facilitate disease spread. There is also need for a review in regional health and immigration 
policy to address issues relating to cross-border movement and TB transmission.   
 
Another area of interest would be, to assess the utility of Oxford nanopore sequencing for further 
understanding of PE/PPE genes in a larger collection of isolates. Although the long reads were 
primarily utilized for assembly of PE/PPE in this thesis, future studies should endeavour to determine 
occurrence of genomic events like homologous recombination across different lineages since some 
of these genes contain long domains with series of repetitive repeats (148). This would highlight how 
the diversity within these genes impacts on the molecular mechanisms responsible for differences in 
virulence and pathogenesis across the different lineages and strains. 
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Finally, there is a need for further research on some of the novel mutations identified in this thesis as 
they were speculated to either contribute to resistance or virulence of the dominant strain. One of 
those mutations is the Thr238Ala, mycP1 that was consistently occurring among MDR/XDR isolates 
hence postulated to play a role towards the acquisition and transmission of drug resistance or 
virulence. Previous studies that utilized M. smegmatis and M. marinum highlighted the dual role 
played by mycp1 in controlling virulence and regulation of ESX-1 secretion; that constitute two key 
immuno-dominant substrates, ESAT-6 and CF-10 (193, 287). Further studies around the mycP1 could 
uncover its potential to be utilized as a drug target especially for drug resistant TB strains or as part 
of a vaccine component.  
 
5.4 Closing remarks 
Overall, WGS is a promising technology to improve TB care and management, in low and high 
burden settings. During this PhD work, WGS revealed the dominance of a modern Beijing strain that 
is responsible for the prevailing drug resistance in the study area and a major threat to the surrounding 
areas. These analyses have not only informed us how the strain has evolved and transmitted, but have 
also highlighted the clinical and epidemiological impact of WGS in high burdened settings. Future 
studies can utilize long read sequencing to provide deeper insights into genetic basis for virulence, 
pathogenesis, transmission and drug resistance evolution; and potential application within clinical 
and public health settings.  
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Appendix II: Supplementary information of chapter 2 
 
Figure S2-1: MIRU-VNTR minimum spanning tree of Mycobacterium tuberculosis isolates collected 
from Daru Island, Papua New Guinea constructed using Bionumerics v6.7. Sectioned circles 
represent two or more isolates that share identical allele profiles. Values on the branches represent 
allelic difference between isolates. Green-dominant cluster (244252352644425163353824), Red-
minor cluster, Purple-unique isolates 
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Figure S2-2: Phylogenetic tree of Daru isolates together with global representative Mycobacterium 
tuberculosis genomes (labels-black). Tree constructed using 7012 single nucleotide polymorphisms 
(using RAxML v.7.4.2) and rooted on Mycobacterium. bovis. The 95 strains formed a monophyletic 
clade (collapse-green) among the modern Beijing sub-lineage while 5 strains were among the Euro-
American lineage (labels-red and purple) 
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Figure S2-3: Pairwise SNP distance among Daru Beijing sub-lineage strains showing a unimodal 
distribution 
 
 
Figure S2-4: Sequence reads mapped of the H37Rv reference showing two rpoB mutations known 
to confer rifampicin resistance. The orange mutation (p.Ile480Val) is outside the 81bp rifampicin 
resistance determining region 
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Figure S2-5: Sequence reads mapped on H37Rv reference genome spanning the rpoB gene (759807- 
763325) but without any observable mutation at sequence depth of X75 
 
 
Figure S2-6: Sequence reads mapped onto H37Rv reference indicating a deletion (2287064-
2291054) spanning pncA gene among two pyrazinamide resistant Beijing strains 
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Figure S2-7: Interaction of genes with SNPs known to confer XDR resistance among Beijing sub-
lineage strains 
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Figure S2-8: Transmission networks constructed using SeqTrack for clades C and D, showing the 
SNP distances (branch numbers). Each circle represents an isolate while larger ones represent two or 
three isolates with similar sequences. Green circle/blue outline-MDR, green circle/red outline-pre-
XDR, red circle-XDR and blue circle-susceptible isolates. Dashed shaped lines represent identified 
clusters of directly linking isolates 
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Table S2-1:  Lineage defined SNPs according to Coll et al (139) 
 
Beijing No Position 
Allele 
change 
Codon 
change 
Gene 
Name 
Coding 
Lineage 2 497491 G/A GAC/GAT glnH Synonymous 
Lineage 2.2 2505085 G/A GCC/GCT cobC Synonymous 
Lineage 2.2.1 797736 C/T CTC/CTT _ Synonymous 
Lineage 2.2.1.1 4248115 C/T GAC/GAT embB Synonymous 
 
 
Table S2-2: Marginal likelihood estimates from Bayesian statistical analysis to test the relaxed 
molecular clock under GTR model for comparison of the different demographics.  
 
Demographic 
model Path sampling Stepping stone 
Bayes 
Factor 
Constant 5905668 5905667  
Logistic 5905637 5905636 31 
Exponential 5905636 5905634 32 
Expansion 5905638 5905634 30 
Bayesian Skyline 5905636 5905636 32 
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Table S2-3: Marginal likelihood estimates for relaxed molecular clocks 
 
Trials Relaxed lognormal Relaxed exponential 
1 6804489 6804589 
2 6804489 6804589 
3 6804490 6804590 
 
 
 
 
Table S2-4: Polymorphisms that are specific to Beijing lineage outbreak cluster Clade B, C and D 
 
 
Position 
Nucleotide 
change Gene Amino Acid Type of change 
635725 G->T Rv0543c Leu51Ile Non-synonymous 
781687 A->G rpsL Lys43Arg Non-synonymous 
844023 T->C fadE9 Asp131Gly Non-synonymous 
950508 AGC->A pdc Rv0853c frameshift 
1595966 CG->C uvrC Rv1420 frameshift 
1611757 C->T Rv1433 Ser108Ser synonymous 
3015445 C->T Rv2700 Thr81Thr synonymous 
3292835 G->C pks1 Ala1173Ala synonymous 
3375035 C->T Rv3015c Ala210Ala synonymous 
4364046 T->C mycp1 Thr238Ala Non-synonymous 
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Appendix III: Supplementary information of chapter 3 
 
Figure S3-1: Trend of notified TB cases among cross-border patients in the Torres Strait Protected 
Zone 
 
 
TB – tuberculosis 
Data provided by the Epidemiology and Research Unit, Queensland Health 
Arrow – closure of TB clinics on the outer islands (commencing mid-2011 with patient handover to 
PNG health authorities completed by mid-2012 through a series of bipartisan clinics) 
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Figure S3-2: Pairwise SNP difference between among all cross-border samples; Red-bars represent 
same MIRU profile, blue-different MIRU and purple-no MIRU profile. SNP difference between all 
possible pairs within the dataset was bi-modal with two large peaks representative of the two lineages 
 
 
Figure S3-3: Number of patients with specific Mycobacterium tuberculosis lineage strains identified 
in each village/town; Purple-Lineage 2(Beijing sub-lineage), checked purple-genomic clusters of 
lineage 2, red-lineage 4 and checked red-genomic clusters of lineage 4 
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Figure S3-4: Molecular clock tree of 83 Beijing sub-lineage strains with parsimonious mapping 
of known resistance conferring mutations. Tree branches with stars (*) are isolates from Australian 
residents, Torres Strait. Clade C and D are previously described (109) 
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Figure S3-6: Pairwise SNP difference among the different lineages identified in the same locality 
and versus different locality; A-Beijing sub-lineage (Mabadauan), B-Beijing sub-lineage (Ture Ture) 
C-Euro-American (Mabadauan), D-comparison of Beijing strains from the same and different 
localities. Eight SNP difference (purple line) was chosen as a threshold to distinguish plausible 
transmission links 
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Table S3-1: MIRU-VNTR profiles identified among the study population 
 
MIRU-VNTR (24 or 15 
loci) profiles 
Number of 
patients 
244252352644425163353824 12 
2_42423_2_4__25163_6___4 6 
2_42423_2_4__25163_5___4 57 
2_42423_2_4__25163_4___4 2 
2_42431_2_3__25153_3___2 5 
2_42132_2_3__26153_3___2 7 
2_43122_1_4__22123_5___3 1 
2_42543_2_2__26153_2___2 2 
2_42232_2_3__26211_5___3 1 
3_43233_2_4__25153_2___2 2 
214213222433226153334502 3 
Missing  6 
Total 104 
  
All the strains from Australian residents had 244252352644425163353824 profile. Underscore (_) 
indicates loci not assessed. Loci were analyzed in the following sequential order: 154, 424 577, 580, 
802, 960, 1644, 1955, 2059, 2163b, 2165, 2347, 2401, 2461, 2531, 2687, 2996, 3007, 3171, 3192, 
3690, 4052, 4156 and 4348.  
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Table S3-2: Lineage defining SNPs for all cross border strains according to Coll et al (139) 
 
   
 
Table S3-3: In-vitro susceptibility results for the study population 
 
 
 
 
 
 
 
 
 
 
 
 
0.1** and 0.4** critical concentration (µg/ml) in MGIT system. *drugs tested if rifampicin resistant 
or on clinical request
Lineage Position 
Allele 
change 
Codon 
change 
Gene 
Name 
Coding 
Spoligotype 
No. of 
strains 
Lineage2.2.1.1 4248115 C/T GAC/GAT embB Synonymous Beijing 83 
Lineage4.1.2.1 107794 C/T  GCC/GCT  fcoT Synonymous X-type 1 
Lineage4.2.1 783601 A/C  AGG/CGG  fusA1  Synonymous TUR 1 
Lineage4.3.1 615614 C/A  GCC/GCA  hemL Synonymous LAM 2 
Lineage4.4.1.1 355181 G/A  AAG/AAA  mycP3  Synonymous S-type 2 
Lineage4.8 3836739 G/A  GAC/GAT  groEL1 Synonymous mainly T 7 
Lineage4.9 1759252 G/T  TCG/TCT  frdA  Synonymous H37Rv-like 8 
TB drug Susceptible Resistant 
Rifampicin 69 35 
Isoniazid0.1** 
53 
20 
Isoniazid0.4** 31 
Ethambutol 94 10 
Pyrazinamide 85 19 
Streptomycin 53 51 
Ethionamide* 1 34 
Ofloxacin* 32 3 
Amikacin* 34 1 
Kanamycin* 33 2 
Capreomycin* 34 1 
PAS* 35 0 
Cycloserine* 35 0 
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Appendix IV: Supplementary information of chapter 4 
Figure S4-1: A scheme of workflow to generate variants from Oxford Nanopore technologies (ONT) 
and Illumina reads 
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Figure S4-2: Dot plot of sequence accuracy between the draft WP-XDR genome and the reference 
genome H37Rv which revealed 99.7% Average Nucleotide Identity (ANI) score. The red dots show 
a forward orientation while blue dots show reverse orientation 
 
129 
 
Figure S4-3: Plot of sequence similarity of 168 PE/PPE family genes identified from the assembly 
and their sequence and depth coverage from Oxford minion® reads. The marks on the x-axis represent 
the different PE/PPE genes while y-axis respects their percentage sequence similarity from blastn 
(red), percentage breadth of coverage (black), and read depth (blue). Sample was sequenced to an 
average depth of 238X 
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Figure S4-4: Plot of sequence and depth coverage for the assembly of 168 PE/PPE family genes 
using Illumina reads. The marks on the x-axis represent the different 168 PE/PPE family genes while 
y-axis respective their percentage breadth of coverage (red), and read depth (blue). Sample was 
sequenced to average 46.3x depth 
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Figure S4-5: Protein structure of the PPE family protein predicted using Phyre2 for a 654bp gene 
sequence with an end 323bp insertion identified within the assembled genome but absent in the 
reference genome H37Rv 
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Table S4-1: List of PE/PPE family genes and their genomic position in H37Rv (NC_000962.3) 
Locus 
Number Gene Start End 
Rv0096 PPE1 105324 106715 
Rv0109 PE_PGRS1 131382 132872 
Rv0124 PE_PGRS2 149533 150996 
Rv0151c PE1 177543 179309 
Rv0152c PE2 179319 180896 
Rv0159c PE3 187433 188849 
Rv0160c PE4 188931 190451 
Rv0256c PPE2 307877 309547 
Rv0278c PE_PGRS3 333437 336310 
Rv0279c PE_PGRS4 336560 339073 
Rv0280 PPE3 339364 340974 
Rv0285 PE5 349624 349932 
Rv0286 PPE4 349935 351476 
Rv0297 PE_PGRS5 361334 363109 
Rv0304c PPE5 366150 372764 
Rv0305c PPE6 372820 375711 
Rv0335c PE6 399535 400050 
Rv0354c PPE7 424269 424694 
Rv0355c PPE8 424777 434679 
Rv0388c PPE9 467459 468001 
Rv0442c PPE10 530751 532214 
Rv0453 PPE11 543174 544730 
Rv0532 PE_PGRS6 622793 624577 
Rv0578c PE_PGRS7 671996 675916 
Rv0742 PE_PGRS8 832981 833508 
Rv0746 PE_PGRS9 835701 838052 
Rv0747 PE_PGRS10 838451 840856 
Rv0754 PE_PGRS11 846159 847913 
Rv0755c PPE12 848103 850040 
Rv0832 PE_PGRS12 924951 925364 
Rv0833 PE_PGRS13 925361 927610 
Rv0834c PE_PGRS14 927837 930485 
Rv0872c PE_PGRS15 968424 970244 
Rv0878c PPE13 976872 978203 
Rv0915c PPE14 1020058 1021329 
Rv0916c PE7 1021344 1021643 
Rv0977 PE_PGRS16 1090373 1093144 
Rv0978c PE_PGRS17 1093361 1094356 
Rv0980c PE_PGRS18 1095078 1096451 
Rv1039c PPE15 1161297 1162472 
Rv1040c PE8 1162549 1163376 
Rv1067c PE_PGRS19 1188421 1190424 
Rv1068c PE_PGRS20 1190757 1192148 
Rv1087 PE_PGRS21 1211560 1213863 
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Rv1088 PE9 1214513 1214947 
Rv1089 PE10 1214769 1215131 
Rv1091 PE_PGRS22 1216469 1219030 
Rv1135c PPE16 1262272 1264128 
Rv1168c PPE17 1298764 1299804 
Rv1169c lipX 1299822 1300124 
Rv1172c PE12 1301755 1302681 
Rv1195 PE13 1339003 1339302 
Rv1196 PPE18 1339349 1340524 
Rv1214c PE14 1357293 1357625 
Rv1243c PE_PGRS23 1384989 1386677 
Rv1325c PE_PGRS24 1488154 1489965 
Rv1361c PPE19 1532443 1533633 
Rv1386 PE15 1561464 1561772 
Rv1387 PPE20 1561769 1563388 
Rv1396c PE_PGRS25 1572127 1573857 
Rv1430 PE16 1606386 1607972 
Rv1441c PE_PGRS26 1618209 1619684 
Rv1450c PE_PGRS27 1630638 1634627 
Rv1452c PE_PGRS28 1636004 1638229 
Rv1468c PE_PGRS29 1655609 1656721 
Rv1548c PPE21 1751297 1753333 
Rv1646 PE17 1855764 1856696 
Rv1651c PE_PGRS30 1862347 1865382 
Rv1705c PPE22 1931497 1932654 
Rv1706c PPE23 1932694 1933878 
Rv1753c PPE24 1981614 1984775 
Rv1759c wag22 1989833 1992577 
Rv1768 PE_PGRS31 2000614 2002470 
Rv1787 PPE25 2025301 2026398 
Rv1788 PE18 2026477 2026776 
Rv1789 PPE26 2026790 2027971 
Rv1790 PPE27 2028425 2029477 
Rv1791 PE19 2029904 2030203 
Rv1800 PPE28 2039453 2041420 
Rv1801 PPE29 2042001 2043272 
Rv1802 PPE30 2043384 2044775 
Rv1803c PE_PGRS32 2044923 2046842 
Rv1806 PE20 2048072 2048371 
Rv1807 PPE31 2048398 2049597 
Rv1808 PPE32 2049921 2051150 
Rv1809 PPE33 2051282 2052688 
Rv1818c PE_PGRS33 2061178 2062674 
Rv1840c PE_PGRS34 2087971 2089518 
Rv1917c PPE34 2162932 2167311 
Rv1918c PPE35 2167649 2170612 
Rv1983 PE_PGRS35 2226244 2227920 
Rv2098c PE_PGRS36 2356729 2358033 
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Rv2099c PE21 2358033 2358206 
Rv2107 PE22 2367359 2367655 
Rv2108 PPE36 2367711 2368442 
Rv2123 PPE37 2381071 2382492 
Rv2126c PE_PGRS37 2387202 2387972 
Rv2162c PE_PGRS38 2423240 2424838 
Rv2328 PE23 2600731 2601879 
Rv2340c PE_PGRS39 2617667 2618908 
Rv2352c PPE38 2632923 2634098 
Rv2353c PPE39 2634528 2635592 
Rv2356c PPE40 2637688 2639535 
Rv2371 PE_PGRS40 2651753 2651938 
Rv2396 PE_PGRS41 2692799 2693884 
Rv2408 PE24 2706017 2706736 
Rv2430c PPE41 2727336 2727920 
Rv2431c PE25 2727967 2728266 
Rv2487c PE_PGRS42 2795301 2797385 
Rv2490c PE_PGRS43 2801254 2806236 
Rv2519 PE26 2835785 2837263 
Rv2591 PE_PGRS44 2921551 2923182 
Rv2608 PPE42 2935046 2936788 
Rv2615c PE_PGRS45 2943600 2944985 
Rv2634c PE_PGRS46 2960105 2962441 
Rv2741 PE_PGRS47 3053914 3055491 
Rv2768c PPE43 3076894 3078078 
Rv2769c PE27 3078158 3078985 
Rv2770c PPE44 3079309 3080457 
Rv2853 PE_PGRS48 3162268 3164115 
Rv2892c PPE45 3200794 3202020 
Rv3018c PPE46 3376939 3378243 
Rv3018A PE27A 3378329 3378415 
Rv3021c PPE47 3379376 3380452 
Rv3022c PPE48 3380440 3380682 
Rv3022A PE29 3380679 3380993 
Rv3097c lipY 3465778 3467091 
Rv3125c PPE49 3490476 3491651 
Rv3135 PPE50 3501334 3501732 
Rv3136 PPE51 3501794 3502936 
Rv3144c PPE52 3510088 3511317 
Rv3159c PPE53 3527391 3529163 
Rv3343c PPE54 3729364 3736935 
Rv3344c PE_PGRS49 3736984 3738438 
Rv3345c PE_PGRS50 3738158 3742774 
Rv3347c PPE55 3743711 3753184 
Rv3350c PPE56 3755952 3767102 
Rv3367 PE_PGRS51 3778568 3780334 
Rv3388 PE_PGRS52 3801653 3803848 
Rv3425 PPE57 3842239 3842769 
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Rv3426 PPE58 3843036 3843734 
Rv3429 PPE59 3847165 3847701 
Rv3477 PE31 3894093 3894389 
Rv3478 PPE60 3894426 3895607 
Rv3507 PE_PGRS53 3926569 3930714 
Rv3508 PE_PGRS54 3931005 3936710 
Rv3511 PE_PGRS55 3939617 3941761 
Rv3512 PE_PGRS56 3941724 3944963 
Rv3514 PE_PGRS57 3945794 3950263 
Rv3532 PPE61 3969343 3970563 
Rv3533c PPE62 3970705 3972453 
Rv3539 PPE63 3978059 3979498 
Rv3558 PPE64 3997980 3999638 
Rv3590c PE_PGRS58 4031404 4033158 
Rv3595c PE_PGRS59 4036731 4038050 
Rv3621c PPE65 4060648 4061889 
Rv3622c PE32 4061899 4062198 
Rv3650 PE33 4091233 4091517 
Rv3652 PE_PGRS60 4093632 4093946 
Rv3653 PE_PGRS61 4093940 4094527 
Rv3738c PPE66 4189285 4190232 
Rv3739c PPE67 4190284 4190517 
Rv3746c PE34 4196171 4196506 
Rv3812 PE_PGRS62 4276571 4278085 
Rv3872 PE35 4350745 4351044 
Rv3873 PPE68 4351075 4352181 
Rv3892c PPE69 4374484 4375683 
Rv3893c PE36 4375762 4375995 
 
Table S4-2: Non-consensus SNPs identified from ONT reads mapped to reference H37Rv (159/1254 
SNPs) 
SNP COUNT 
Proportion 
(%) 
A->C 6 0.48 
A->G 15 1.20 
T->C 18 1.44 
T-G 13 1.04 
C->A 9 0.72 
C->T 19 1.52 
C->G 23 1.83 
G->A 22 1.75 
G->T 20 1.59 
G->C 14 1.12 
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Table S4-3: Number of SNPs and average base coverage identified from different assembled PE/PPE 
family genes from ONT and Illumina reads 
PE/PPE 
genes 
ONT Illumina 
Overlap 
SNPs 
Illumina 
average 
base 
coverage 
ONT 
average 
base 
coverage 
PPE1 1 1 1 46 273 
PE_PGRS1 1 0 0 24 332 
PE1 1 1 1 65 279 
PE3 1 1 1 79 281 
PPE2 2 2 2 47 307 
PPE3 1 2 2 61 305 
PPE6 2 2 2 59 269 
PPE47 0 14 0 19 232 
PPE8 4 4 4 53 288 
PE_PGRS6 3 0 0 12 307 
PE_PGRS7 4 2 2 18 338 
PPE9 0 9 0 35 323 
PE_PGRS9 2 0 0 11 244 
PE_PGRS10 6 4 4 14 257 
PE_PGRS13 3 0 0 6 261 
PE_PGRS14 1 0 0 35 318 
PE_PGRS15 1 0 0 24 304 
PE_PGRS17 3 1 1 44 310 
PE_PGRS18 4 0 0 39 307 
PPE16 0 3 0 44 234 
PE8 1 1 1 66 292 
PE_PGRS20 4 0 0 31 339 
PE_PGRS44 0 2 0 37 339 
PE_PGRS21 2 0 0 29 315 
PE_PGRS22 5 2 2 20 328 
PPE17 1 1 1 56 288 
PPE18 1 0 0 60 270 
PE14 1 1 1 53 305 
PPE19 2 0 0 74 296 
PPE20 1 1 1 59 292 
PPE31 0 1 0 62 313 
PE_PGRS25 1 1 1 23 289 
PE16 1 1 1 69 289 
PE_PGRS26 1 1 1 37 348 
PE_PGRS27 2 0 0 21 318 
PE_PGRS28 6 3 3 30 313 
PPE21 1 0 0 59 299 
PPE22 1 1 1 53 308 
PPE24 2 0 0 47 274 
PPE30 1 0 0 63 288 
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PE_PGRS32 3 1 1 22 317 
PPE32 2 0 0 57 283 
PPE33 2 2 2 75 283 
PE_PGRS33 1 0 0 26 311 
PPE34 2 3 2 68 234 
PPE35 2 1 1 51 265 
PPE37 1 0 0 64 268 
PE_PGRS37 1 0 0 9 321 
PE23 2 2 2 62 292 
PE24 1 1 1 69 274 
PE_PGRS42 1 0 0 26 314 
PE_PGRS43 8 0 0 15 295 
PE26 1 1 1 55 287 
PE_PGRS47 4 0 0 30 329 
PE27 2 2 2 73 283 
PPE44 1 1 1 70 289 
PE_PGRS48 3 1 1 39 293 
lipY 2 1 1 66 310 
PPE51 1 0 0 59 279 
PPE52 1 0 0 39 287 
PPE53 1 0 0 90 373 
PPE54 11 9 9 67 338 
PE_PGRS50 1 1 1 28 403 
PPE55 7 17 7 51 267 
PPE56 3 3 3 45 263 
PPE60 2 2 2 66 275 
PE_PGRS53 1 0 0 26 402 
PE_PGRS54 7 4 4 17 325 
PE_PGRS55 1 1 1 36 368 
PE_PGRS56 3 6 3 30 374 
PE_PGRS58 2 1 1 18 307 
PE_PGRS59 1 0 0 18 320 
PPE66 1 1 1 58 334 
PE35 1 0 0 60 296 
PPE69 1 1 1 59 313 
Total 158 124 81   
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Table S4-4: Mutations identified in genes that encode for potential virulence proteins in the WP-
XDR strain 
Gene 
Nucleotide 
change 
Position Amino acid 
mak T->C 154283 p.Ser18Pro 
mce1A T->G 199470 p.Ser313Ala 
mce1D T->C 203038 p.Ile188Thr 
mce1F T->C 206339 p.Leu370Pro 
mce2A T->C 686972 p.Phe51Ser 
mce2F A->G 694531 p.Asn432Ser 
Rv0634c A->G 731015 p.Tyr7His 
mazF3 G->A 1230778 p.Thr65Ile 
ephB G->T 2191498 p.Gly158Trp 
mce3A G->A 2209465 p.Ala47Thr 
mce3F C->A 2216443 p.Ala396Glu 
cstA C->A 3428917 p.Arg559Ser 
mce4C G->T 3916386 pArg191Ser 
proV T->C 4204168 p.Asn84Asp 
proX A->G 4205120 p.Leu85Pro 
mycP1 T->C 4364046 Thr238Ala 
 
XDR - Extensively drug resistant 
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Table S4-5: Mutations in genes involved in cell wall biosynthesis identified in the WP-XDR strain 
Gene Position Mutation 
mmpL5 776182 p.Asp767Asn 
mmpL12 1715165 p.Ile816Met 
mmpL10 1322741 p.Thr408Ala 
fadD6 1349733 p.Glu134Asp 
fadE9 844023 p.Asp131Gly 
fadD28 3284640 p.Thr436Ala 
fadD30 484596 p.Pro207Leu 
fadD34 37305 p.Ser16Trp 
fadD34 37334 p.Thr26Ser 
fadD36 1336164 p.Pro124Leu 
fadD31 2177366 p.Arg94Cys 
fadE17 2185674 p.Ile172Thr 
fadE20 3036826 p.Val156Met 
fadD28 3284640 p.Thr436Ala 
fadE24 3505648 p.Arg96Gly 
fadE26 3922552 p.Leu218Met 
fadD19 3952308 p.Asp55Tyr| 
fadE35 4252066 p.Ser328Pro 
fadD32 4262388 p.Gly227Ser 
fadD23 4301075 p.Glu422Gln 
pks5 1722228 p.Leu2061Arg 
pks7 1876976 p.Thr558Lys 
pks8 1885385 p.Leu1228Val 
pks11 1891388 p.Pro55Ala 
pks12 2295685 p.Val3768Leu 
pks12 2302033 p.Arg1652Cys 
pks13 4256210 p.Ala1646Asp 
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Table S4-6: Blast search results of the gene sequence with insertion confirming the uniqueness of 
insertion sequence among lineage 2 genomes 
Query 
Number 
Reference 
genomes 
Identification 
(%) 
Identified 
(bp) 
Query 
coverage 
(%) 
start end 
E-
value 
Max 
score 
117001 CP007027.1 100 332 50 3500716 3501047 
1.11E-
175 614 
117001 CP009480.1 100 332 50 3494479 3494810 
1.11E-
175 614 
117001 CP003248.2 100 332 50 3501331 3501662 
1.11E-
175 614 
117001 AL123456.3 100 332 50 3501334 3501665 
1.11E-
175 614 
159769 CP022014.1 100 654 100 3502186 3502839 0.00 654 
159769 AP018036.1 100 654 100 3489334 3489987 0.00 654 
159769 AP018035.1 100 654 100 3498189 3498842 0.00 654 
159769 AP018034.1 100 654 100 3486855 3487508 0.00 654 
159769 CP017920.1 100 654 100 4292533 4291880 0.00 654 
159769 CP013475.1 100 654 100 3481453 3482106 0.00 654 
159769 CP011510.1 100 654 100 4254434 4253781 0.00 654 
159769 CP016888.1 100 654 100 3496444 3497097 0.00 654 
159769 CP012506.2 100 654 100 3493237 3493890 0.00 654 
159769 CP016794.1 100 654 100 3493988 3494641 0.00 654 
159769 CP010968.1 100 654 100 3981473 3982126 0.00 654 
159769 CP010339.1 100 654 100 3499781 3500434 0.00 654 
159769 CP010335.1 100 654 100 3493892 3494545 0.00 654 
159769 CP012090.1 100 654 100 917081 916428 0.00 654 
159769 CP010895.1 100 654 100 3955706 3956359 0.00 654 
159769 CP007299.1 100 654 100 3490224 3490877 0.00 654 
159769 HG813240.1 100 654 100 3491900 3492553 0.00 654 
159769 CP009426.1 100 654 100 3470402 3471055 0.00 654 
159769 CP008983.1 100 654 100 518032 517379 0.00 654 
159769 CP008981.1 100 654 100 518033 517380 0.00 654 
159769 CP008980.1 100 654 100 518033 517380 0.00 654 
159769 CP008979.1 100 654 100 518032 517379 0.00 654 
159769 CP008978.1 100 654 100 518033 517380 0.00 654 
159769 CP008977.1 100 654 100 518032 517379 0.00 654 
159769 CP008976.1 100 654 100 518032 517379 0.00 654 
159769 CP008975.1 100 654 100 518032 517379 0.00 654 
159769 CP008974.1 100 654 100 518032 517379 0.00 654 
159769 CP008973.1 100 654 100 518033 517380 0.00 654 
159769 CP008972.1 100 654 100 518033 517380 0.00 654 
159769 CP008970.1 100 654 100 518032 517379 0.00 654 
159769 CP008969.1 100 654 100 518033 517380 0.00 654 
159769 CP008968.1 100 654 100 518032 517379 0.00 654 
159769 CP008966.1 100 654 100 518032 517379 0.00 654 
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159769 CP008964.1 100 654 100 518032 517379 0.00 654 
159769 CP008962.1 100 654 100 518033 517380 0.00 654 
159769 CP008961.1 100 654 100 518032 517379 0.00 654 
159769 CP008960.1 100 654 100 518033 517380 0.00 654 
159769 CP008959.1 100 654 100 518033 517380 0.00 654 
159769 CP007809.1 100 654 100 3488153 3488806 0.00 654 
159769 CP007803.1 100 654 100 3478240 3478893 0.00 654 
159769 CP002885.1 100 654 100 3491717 3492370 0.00 654 
159769 CP002883.1 100 654 100 3486486 3487139 0.00 654 
159769 CP002882.1 100 654 100 3480758 3481411 0.00 654 
159769 CP002871.1 100 654 100 3490732 3491385 0.00 654 
159769 CP002884.1 100 654 100 3492943 3493596 0.00 654 
159769 CP001642.1 100 654 100 3486529 3487182 0.00 654 
159769 CP001641.1 100 654 100 3478627 3479280 0.00 654 
159769 CP017598.1 100 654 100 3495720 3496373 0.00 654 
159769 CP017597.1 100 654 100 3522988 3523641 0.00 654 
159769 CP017596.1 100 654 100 3493170 3493823 0.00 654 
159769 CP017595.1 100 654 100 3508711 3509364 0.00 654 
159769 CP017594.1 100 654 100 3519190 3519843 0.00 654 
159769 CP017593.1 100 654 100 3505356 3506009 0.00 654 
159769 CP010873.1 100 654 100 3488175 3488828 0.00 654 
159769 CP008963.1 100 654 100 518033 517379 0.00 654 
 
 
 
